+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

List of PDF Full Texts available from EurekaMag Chapter 49905

Chapter 49905 contains a list of PDF Full Texts available from EurekaMag.





Hansen, K.; Lançon, C.; Toumi, M., 2006:
Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?

Stratchounski, L.S.; Rozenson, O.L., 2006:
Pharmacoeconomic perspectives in Russia

Wawruch, M.; Bozeková, L.; Krcméry, S.; Kozlíková, K.; Foltán, V.; Lassánová, M.; Kriska, M., 2005:
Pharmacoeconomic profile of antibiotics used in the treatment of lower respiratory tract infections in geriatric patients

Postma, M.J., 2003:
Pharmacoeconomic research

Bartkó, Görgy.; Fehér, László., 2006:
Pharmacoeconomic review of the use of injectable long-acting risperidone

Cornago, D.; Li Bassi, L.; De Compadri, P.; Garattini, L., 2006:
Pharmacoeconomic studies in Italy: a critical review of the literature

Miravitlles, M.; Jardim, J.R.; Zitto, T.; Rodrigues, J.E.; López, H., 2003:
Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America

Rapeport, D.; Harper, S.; Flisberg, P., 2005:
Pharmacoeconomic viewpoints on volatile anaesthesia--"much ado about nothing?"

Rudakova, A.V., 2004:
Pharmacoeconomical aspects of the use of angiotensin converting enzyme inhibitors in clinical practice (lisinopril use)

Ostroumova, O.D.; Mamaev, V.I.; Ishchenko, K.A.; Shorikova, E.G., 2003:
Pharmacoeconomical aspects of the use of beta-blockers in hypertension and heart failure

Sokolova, O.P., 2006:
Pharmacoeconomical grounds for decision on a basic hypnotic for general anesthesia in surgical interventions

Anguita Sánchez, M., 2004:
Pharmacoeconomics and cardiovascular disease

Cosler, L.E., 2003:
Pharmacoeconomics and considerations for injectable products: focus on colony-stimulating factors

Ariza, J.Guillermo.; Martínez, J.Andrés., 2006:
Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod

Briggs, A.H.; Levy, A.R., 2006:
Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?

Tatsch, F.Franciosi.; Sette, H.; Vianna, D., 2006:
Pharmacoeconomics applied to chronic hepatitis C

Nuijten, M.J., 2006:
Pharmacoeconomics in European decision-making

Jones, J.Spencer., 2006:
Pharmacoeconomics in South Africa

Wozakowska-Kapłon, B.; Kempkiewicz, T., 2006:
Pharmacoeconomics in cardiovascular disease. Part 1: pharmacoeconomics in coronary heart disease

Wozakowska-Kapłon, B.; Kempkiewicz, T., 2006:
Pharmacoeconomics in cardiovascular disease. Part 2: pharmacoeconomics in congestive heart failure and arterial hypertension

Czech, M., 2004:
Pharmacoeconomics in contemporary medicine

Postma, M.J.; Boersma, C.; Gansevoort, R.T., 2007:
Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria

Ariano, R.; Berto, P.; Tracci, D.; Incorvaia, C.; Frati, F., 2006:
Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma

Boersma, C.; Atthobari, J.; Gansevoort, R.T.; de Jong-Van den Berg, L.T.W.; de Jong, P.E.; de Zeeuw, D.; Annemans, L.J.P.; Postma, M.J., 2006:
Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making

Szucs, T.D.; Bramkamp, M., 2006:
Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review

Johnson, M.D.; Kleinberg, M.; Danziger, L.; Ostrosky-Zeichner, L., 2005:
Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions

Degli Esposti, L.; Di Martino, M.; Saragoni, S.; Sgreccia, A.; Capone, A.; Buda, S.; Esposti, E.Degli., 2004:
Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies

Jahnz-Rózyk, K.; Targowski, T., 2004:
Pharmacoeconomics of asthma

Cleland, J.; Thomas, M.; Price, D., 2003:
Pharmacoeconomics of asthma treatment

Bushnell, C.D.; Matchar, D.B., 2004:
Pharmacoeconomics of atrial fibrillation and stroke prevention

Jönsson, L., 2003:
Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease

DeRyke, C.Andrew.; Kuti, J.L.; Mansfield, D.; Dana, A.; Nicolau, D.P., 2006:
Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection

Kusowska, J., 2006:
Pharmacoeconomics of dyspesia and peptic ulcer disease

Postma, M.J.; Heijnen, M-Louise.A.; Beutels, P.; Jager, J.C., 2004:
Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands

Chernin, E.L., 2004:
Pharmacoeconomics of inhaled anesthetic agents: considerations for the pharmacist

Bennett, C.L.; Calhoun, E.A., 2005:
Pharmacoeconomics of liposomal anthracycline therapy

Haycox, A., 2006:
Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models

Jones, T.E.; Smith, B.J.; Polasek, J.F., 2004:
Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin

Murthy, A.; Creinin, M.D., 2003:
Pharmacoeconomics of medical abortion: a review of cost in the United States, Europe and Asia

Laux, G., 2004:
Pharmacoeconomics of modern antidepressives

Kiess, W.; Böttner, A.; Blüher, S.; Raile, K.; Seidel, B.; Kapellen, T.; Keller, E.; Kratzsch, Jürgen., 2003:
Pharmacoeconomics of obesity management in childhood and adolescence

Bordeleau, L., 2006:
Pharmacoeconomics of systemic therapies for lung cancer

Wang, L.; Barrett, J.F., 2006:
Pharmacoeconomics of treatment with the newer anti-Gram-positive agents

Karpov, O.I., 2003:
Pharmacoeconomics of ulcers: a view from Saint-Petersburg

Słominski, J.Marek.; Kubiak, A., 2004:
Pharmacoeconomics of vaccinations in chronic obstructive pulmonary disease

Curtiss, F.R., 2003:
Pharmacoeconomics--determination of the cost-effectiveness of Helicobacter pylori eradication

Pedersen, K.Møller., 2003:
Pharmacoeconomics--survey and status

Bootman, J.Lyle.; McGhan, W.F.; Townsend, R.J., 2006:
Pharmacoeconomics: historical perspective

Gagnon, J.P.; Smith, M.D.; Rindress, D., 2006:
Pharmacoeconomics: identifying the issues overview and advisory panel report summary

Luchins, D.J., 2004:
Pharmacoeconomics: the new dismal science

Motwani, B.; Khayr, W., 2006:
Pharmacoenhancement of protease inhibitors

Rachin, A.P.; Iudel'son, I.B., 2005:
Pharmacoepidemiological aspects of chronic daily headache

Etminan, M., 2004:
Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmacoepidemiologic research

Savo, A.; Maiorano, P.Maria.; Onder, G.; Bernabei, R., 2004:
Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?

Anonymous, 2003:
Pharmacoepidemiology and drug safety

Anonymous, 2004:
Pharmacoepidemiology and drug safety

Anonymous, 2004:
Pharmacoepidemiology and drug safety

Vitiello, B., 2005:
Pharmacoepidemiology and pediatric psychopharmacology research

Chan, K.Arnold.; Hernandez-Diaz, S., 2004:
Pharmacoepidemiology and rheumatic disorders

Verdoux, Hélène.; Tournier, M.; Cougnard, A.; Martin, K.; Bégaud, B., 2006:
Pharmacoepidemiology of psychotropic medication: utilisation and impact in real-life conditions

Fautrel, B., 2004:
Pharmacoepidemiology: lessons from real life

Morf, H.; Moritz, O., 1956:
Pharmacoergastric examinations of Bergenia leaves; contribution to the pathology and physiology of dessication

Rumler, W., 1964:
Pharmacogenetic And Undesirable Drug Effects

Fischer, R.; Griffin, F., 1964:
Pharmacogenetic Aspects Of Gustation

Kirstein-Grossman, I.; Beckmann, J.S..; Lancet, D.; Miller, A., 2003:
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model

Rose, C.M.; Marsh, S.; Ameyaw, M-Mary.; McLeod, H.L., 2003:
Pharmacogenetic analysis of clinically relevant genetic polymorphisms

Hasegawa, Y.; Ando, Y.; Ando, M.; Hashimoto, N.; Imaizumi, K.; Shimokata, K., 2006:
Pharmacogenetic approach for cancer treatment-tailored medicine in practice

Sayers, I.; Hall, I.P., 2005:
Pharmacogenetic approaches in the treatment of asthma

Stoehlmacher, J.; Goekkurt, E.; Lenz, H.Josef., 2003:
Pharmacogenetic aspects in treatment of colorectal cancer--an update

Zhang, Z.; Hou, G.; Zhang, X.; Yao, H.; Sha, W.; Zhang, X., 2003:
Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)

Breen, D.P.; Marinaki, A.M.; Arenas, M.; Hayes, P.C., 2005:
Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation

Ando, Y.; Price, D.K.; Dahut, W.L.; Cox, M.C.; Reed, E.; Figg, W.D., 2003:
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide

Hull, C.; Larson, A.; Leachman, S., 2003:
Pharmacogenetic candidate genes for melanoma

Sukhanov, V.A.; Piruzian, L.A., 2004:
Pharmacogenetic challenges in the treatment of mental diseases

Klees, T.Mariero.; Sheffels, P.; Thummel, K.E.; Kharasch, E.D., 2005:
Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5

Warrington, J.S.; Shaw, L.M., 2006:
Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy

Tan, B.R.; McLeod, H.L., 2005:
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer

Rai, A.K., 2003:
Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis

Judson, R.S.; Salisbury, B.A.; Reed, C.R.; Ackerman, M.J., 2006:
Pharmacogenetic issues in thorough QT trials

Sykiotis, G.P.; Kalliolias, G.D.; Papavassiliou, A.G., 2005:
Pharmacogenetic principles in the Hippocratic writings

Ruzzo, A.; Graziano, F.; Kawakami, K.; Watanabe, G.; Santini, D.; Catalano, V.; Bisonni, R.; Canestrari, E.; Ficarelli, R.; Menichetti, E.Tito.; Mari, D.; Testa, E.; Silva, R.; Vincenzi, B.; Giordani, P.; Cascinu, S.; Giustini, L.; Tonini, G.; Magnani, M., 2006:
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy

Relling, M.V.; Yang, W.; Das, S.; Cook, E.H.; Rosner, G.L.; Neel, M.; Howard, S.; Ribeiro, R.; Sandlund, J.T.; Pui, C-Hon.; Kaste, S.C., 2004:
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia

Bosch, T.M.; Doodeman, V.D.; Smits, P.H.M.; Meijerman, I.; Schellens, J.H.M.; Beijnen, J.H., 2006:
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population

Bosch, T.M.; Huitema, A.D.R.; Doodeman, V.D.; Jansen, R.; Witteveen, E.; Smit, W.M.; Jansen, R.L.; van Herpen, C.M.; Soesan, M.; Beijnen, J.H.; Schellens, J.H.M., 2006:
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel

Lane, H-Yuan.; Lee, C-Chun.; Liu, Y-Ching.; Chang, W-Ho., 2005:
Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

Rodríguez-Villanueva, J.; Alsar, M.Jesús.; Avendaño, C.; Gómez-Piqueras, C.; García-Alonso, F., 2003 :
Pharmacogenetic studies: evaluation guidelines for research ethics committees. Study protocol and patient information sheet (II)

Kolik, L.G.; Gudasheva, T.A.; Seredenin, S.B., 2003:
Pharmacogenetic study of anxiolytic effects of new cholecystokinin receptor antagonists in animals with different levels of emotionality

Inoue, S.; Hashiguchi, M.; Chiyoda, T.; Sunami, Y.; Tanaka, T.; Mochizuki, M., 2006:
Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences

Marian, A.J., 2005:
Pharmacogenetic study of statin therapy and cholesterol reduction

Martínez-Sellés, M.; Castillo, I.; Montenegro, P.; Martín, Mía.L.; Almendral, Jús.; Sanjurjo, Mía., 2005:
Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation

Corominas, H.; Díaz, C.; Vázquez, G.; Baiget, M., 2003:
Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity

Netzer, C.; Biller-Andorno, N., 2004:
Pharmacogenetic testing, informed consent and the problem of secondary information

Jaillon, P., 2006:
Pharmacogenetic testing: utility in drug development and in routine clinical practice

Apud, Jé.A.; Weinberger, D.R., 2006:
Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs

Morrow, T., 2004:
Pharmacogenetic, pharmacogenomic testing rapidly gaining acceptance

Theilade, M.Due., 2005:
Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency

Hansen, L.; Andersen, D., 2005:
Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry

Padrini, R.; Ferrari, M., 2003:
Pharmacogenetics

David, S.P., 2004:
Pharmacogenetics

Mealey, K.L., 2006:
Pharmacogenetics

Goedde, H.W.; Schoepf, E., 1964:
Pharmacogenetics (Clinical Problems And Biochemicogenetic Bases)

Daudén Tello, E., 2006:
Pharmacogenetics I. Concept, history, objectives and areas of study

Matthew, J.R.; Constan, E., 1964:
Pharmacogenetics In Pre-Ect Medication

Brown, A.M., 1965:
Pharmacogenetics Of The Mouse

Galley, H.F.; Mahdy, A.; Lowes, D.A., 2005:
Pharmacogenetics and anesthesiologists

Clancy, C.E.; Zhu, Z.I.; Rudy, Y., 2006:
Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation

Gage, B.F.; Eby, C.S., 2004:
Pharmacogenetics and anticoagulant therapy

Fontana, P.; Reny, J-L., 2005:
Pharmacogenetics and antiplatelet drugs

Weston, C.F.M., 2004:
Pharmacogenetics and cardiovascular disease management

Hisamuddin, I.M.; Wehbi, M.A.; Yang, V.W., 2006:
Pharmacogenetics and diseases of the colon

Vandel, P.; Talon, J.M.; Haffen, E.; Sechter, D., 2007:
Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism

Rahemtulla, T.; Bhopal, R., 2005:
Pharmacogenetics and ethnically targeted therapies

Kahn, J.D., 2005:
Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context

Kreek, M.Jeanne.; Bart, G.; Lilly, C.; LaForge, K.Steven.; Nielsen, D.A., 2005:
Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments

Ho, G-Tzer.; Lees, C.; Satsangi, J., 2004:
Pharmacogenetics and inflammatory bowel disease: progress and prospects

Becquemont, L.; Verstuyft, Céline.; Jaillon, P., 2006:
Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants

Hahn, K.K.; Wolff, J.J.; Kolesar, J.M., 2006:
Pharmacogenetics and irinotecan therapy

Liakhovich, V.V.; Vavilin, V.A.; Grishanova, A..Iu.; Makarova, S.I.; Kovalenko, S.P., 2004:
Pharmacogenetics and modern medicine

Munafò, M.R.; Shields, A.E.; Berrettini, W.H.; Patterson, F.; Lerman, C., 2005:
Pharmacogenetics and nicotine addiction treatment

Marsh, S.; McLeod, H.L., 2007:
Pharmacogenetics and oncology treatment for breast cancer

Kalow, W., 2003:
Pharmacogenetics and personalised medicine

Latif, D.A., 2005:
Pharmacogenetics and pharmacogenomics instruction in schools of pharmacy in the USA: is it adequate?

Schmitz, G.; Schmitz-Madry, A.; Ugocsai, P., 2007:
Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy

Yan, L.; Davis, H.M., 2006:
Pharmacogenetics and pharmacogenomics of therapeutic monoclonal antibodies

Brand, E., 2003:
Pharmacogenetics and pharmacogenomics. Searching for individual antihypertensive therapy concepts

Weinshilboum, R.M.; Wang, L., 2006:
Pharmacogenetics and pharmacogenomics: development, science, and translation

Loni, L.; De Braud, F.; Zinzani, P.Luigi.; Danesi, R., 2004:
Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma

Basu, A.; Tsapakis, E.; Aitchison, K., 2004:
Pharmacogenetics and psychiatry

Melzer, D.; Detmer, D.; Zimmern, R., 2003:
Pharmacogenetics and public policy: expert views in Europe and North America

Muszkat, M.; Stein, C.Michael., 2005:
Pharmacogenetics and response to beta-adrenergic receptor antagonists in heart failure

Asanuma, Y.; Xie, H-Guang.; Stein, C.Michael., 2005:
Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response

Andreassen, O.A.; Steen, V.M., 2006:
Pharmacogenetics and tailored drug treatment in schizophrenia

Ling, T.; Raven, A., 2006:
Pharmacogenetics and uncertainty: implications for policy makers

Wilffert, B.; Zaal, R.; Brouwers, J.R.B.J., 2005:
Pharmacogenetics as a tool in the therapy of schizophrenia

Bukaveckas, B.L.; Valdes, R.; Linder, M.W., 2004:
Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia

Efferth, T.; Volm, M., 2005:
Pharmacogenetics for individualized cancer chemotherapy

Ozdemir, V.; Aklillu, E.; Mee, S.; Bertilsson, L.; Albers, L.J.; Graham, J.E.; Caligiuri, M.; Lohr, J.B.; Reist, C., 2006:
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

Brdicka, R., 2005:
Pharmacogenetics from the aspect of the Coordinating Group for Pharmacogenetics of OECD

Kilborn, M., 2005:
Pharmacogenetics in Evidence-based practice--what to watch for

Rodríguez-Nóvoa, S.; Barreiro, P.; Jiménez-Nacher, I.; Rendón, A.; Soriano, V., 2005:
Pharmacogenetics in HIV therapy

Constable, S.; Johnson, M.R.; Pirmohamed, M., 2006:
Pharmacogenetics in clinical practice: considerations for testing

Wu, X.; Lu, C.; Chiang, S.S.; Ajani, J.A., 2006:
Pharmacogenetics in esophageal cancer

Rogausch, A.; Brockmöller, J.; Himmel, W., 2005:
Pharmacogenetics in future medical care -- implications for patients and physicians

Maitland-van, d.Zee.Anke-Hilse.; Klungel, O.H.; de Boer, A., 2004:
Pharmacogenetics in health-care practice

McNamara, D.M., 2004:
Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function

Pierik, M.; Rutgeerts, P.; Vlietinck, R.; Vermeire, S., 2006:
Pharmacogenetics in inflammatory bowel disease

Nnadi, C.U.; Goldberg, J.F.; Malhotra, A.K., 2006:
Pharmacogenetics in mood disorder

Depondt, C., 2007:
Pharmacogenetics in neuropsychiatric diseases: epilepsy as a model

Greb, R.R.; Behre, H.M.; Simoni, M., 2006:
Pharmacogenetics in ovarian stimulation - current concepts and future options

Collier, D.A., 2003:
Pharmacogenetics in psychosis

Blackhall, F.H.; Howell, S.; Newman, B., 2006:
Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment

Greaves, M., 2005:
Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?

Cronstein, B.N., 2006:
Pharmacogenetics in the rheumatic diseases

Tellería Orriols, J.J.; Blanco Quirós, A., 2006:
Pharmacogenetics in the treatment of asthma

Burckart, G.J.; Liu, X.I., 2006:
Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?

Altavilla, G.; Marabello, G., 2004:
Pharmacogenetics in tumors of the lung

Sakaeda, T.; Nakamura, T.; Okumura, K., 2003:
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs

Weinstock-Guttman, B.; Tamaño-Blanco, M.; Bhasi, K.; Zivadinov, R.; Ramanathan, M., 2006:
Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients

Xiang, X.; Jada, S.Rao.; Li, H.Hua.; Fan, L.; Tham, L.San.; Wong, C.Ing.; Lee, S.Chin.; Lim, R.; Zhou, Q.Yu.; Goh, B.Cher.; Tan, E.Huat.; Chowbay, B., 2006:
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients

Mehta, P.A.; Davies, S.M., 2004:
Pharmacogenetics of acute lymphoblastic leukemia

Knoche, E.; McLeod, H.L.; Graubert, T.A., 2006:
Pharmacogenetics of alkylator-associated acute myeloid leukemia

Stamer, U.M.; Stuber, F., 2005:
Pharmacogenetics of anesthetic and analgesic agents: CYP2D6 genetic variations

Coto, E.; Marín, R.; Alvarez, V.; Praga, M.; Fernández Andrade, C.; Arias, M.; Poveda, R.; Vallés, M.; Galcerán, J.M.; Luño, J.; Rivera, F.; Campistol, J.M., 2005:
Pharmacogenetics of angiotensin system in non diabetic nephropathy

Nguyen, T.V., 2005:
Pharmacogenetics of anti-resorptive therapy efficacy: a Bayesian interpretation

Darbar, D.; Roden, D.M., 2006:
Pharmacogenetics of antiarrhythmic therapy

Murphy, G.M.; Kremer, C.; Rodrigues, H.E.; Schatzberg, A.F., 2003:
Pharmacogenetics of antidepressant medication intolerance

Kreutz, R., 2004:
Pharmacogenetics of antihypertensive drug response

Schwartz, G.L.; Turner, S.T., 2004:
Pharmacogenetics of antihypertensive drug responses

Arnett, D.K.; Claas, S.A.; Glasser, S.P., 2005:
Pharmacogenetics of antihypertensive treatment

Arbouw, M.E.L.; van Vugt, J.P.P.; Egberts, T.C.G.; Guchelaar, H-Jan., 2007:
Pharmacogenetics of antiparkinsonian drug treatment: a systematic review

Curtin, R.; Fitzgerald, D.J., 2003:
Pharmacogenetics of antiplatelet drugs

Ozaki, N., 2004:
Pharmacogenetics of antipsychoatics

Lerer, B.; Segman, R.H., 2006:
Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation

Bondy, B.; Spellmann, I., 2007:
Pharmacogenetics of antipsychotics: useful for the clinician?

Martin, A.M.; Nolan, D.; Gaudieri, S.; Phillips, E.; Mallal, S., 2004:
Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity

Tàssies, D., 2006:
Pharmacogenetics of antithrombotic drugs

Hall, I.P., 2006 :
Pharmacogenetics of asthma

Mialet-Perez, J.; Liggett, S.B., 2006:
Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension

Taylor, D.Robin., 2006:
Pharmacogenetics of beta2-agonist drugs in asthma

Largillier, Rémy.; Etienne-Grimaldi, M-Christine.; Formento, J-Louis.; Ciccolini, J.; Nebbia, J-François.; Ginot, Aélie.; Francoual, M.; Renée, N.; Ferrero, J-Marc.; Foa, C.; Namer, Mïse.; Lacarelle, B.; Milano, Gérard., 2006:
Pharmacogenetics of capecitabine in advanced breast cancer patients

Johnson, J.A.; Humma, L.M., 2004:
Pharmacogenetics of cardiovascular drugs

Zineh, I.; Johnson, J.A., 2006:
Pharmacogenetics of chronic cardiovascular drugs: applications and implications

Vasků, A.; Spinarová, L.; Pávková-Goldbergová, M.; Spinar, J.; Soucek, M.; Vítovec, J., 2006:
Pharmacogenetics of chronic heart failure--beta blockers

Marsh, S., 2005:
Pharmacogenetics of colorectal cancer

de Castro, F.; Morón, F.J.; Montoro, L.; Real, L.M.; Ruiz, Aín., 2005:
Pharmacogenetics of controlled ovarian hyperstimulation

Ribeiro, V.; Cavaco, I., 2006:
Pharmacogenetics of cytochromes P450 in tropical medicine

Tanaka, E.; Taniguchi, A.; Urano, W.; Yamanaka, H.; Kamatani, N., 2004 :
Pharmacogenetics of disease-modifying anti-rheumatic drugs

Scharfetter, J., 2004:
Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update

Sills, G.J., 2005:
Pharmacogenetics of epilepsy: one step forward?

Robien, K.; Boynton, A.; Ulrich, C.M., 2005:
Pharmacogenetics of folate-related drug targets in cancer treatment

Novelli, G.; Margiotti, K.; Chiocca, A.Maria.; Spera, E.; Micali, F.; Reichardt, J.K.V., 2004:
Pharmacogenetics of human androgens and prostate cancer--an update

Sychov, D.A.; Kropacheva, E.S.; Ignat'ev, I.V.; Bulytova, I.M.; Dobrovol'skiĭ, A.B.; Panchenko, E.P.; Kukes, V.G., 2006:
Pharmacogenetics of indirect anticoagulants: value of genotype for improvement of efficacy and safety of therapy

Kelleher, D.; Farrell, R.; McManus, R., 2005:
Pharmacogenetics of inflammatory bowel disease

Marsh, S.; McLeod, H.L., 2004:
Pharmacogenetics of irinotecan toxicity

Innocenti, F.; Ratain, M.J., 2006:
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

Krajinovic, M.; Moghrabi, A., 2004:
Pharmacogenetics of methotrexate

Glatt, C.E.; Reus, V.I., 2003:
Pharmacogenetics of monoamine transporters

Koren, G.; Cairns, J.; Chitayat, D.; Gaedigk, A.; Leeder, S.J., 2006:
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

Haas, D.W.; Bartlett, J.A.; Andersen, J.W.; Sanne, I.; Wilkinson, G.R.; Hinkle, J.; Rousseau, F.; Ingram, C.D.; Shaw, A.; Lederman, M.M.; Kim, R.B., 2006:
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration

Swan, G.E.; Benowitz, N.L.; Jacob, P.; Lessov, C.N.; Tyndale, R.F.; Wilhelmsen, K.; Krasnow, R.E.; McElroy, M.R.; Moore, S.E.; Wambach, M., 2004:
Pharmacogenetics of nicotine metabolism in twins: methods and procedures

Mayer, P.; Höllt, V., 2005:
Pharmacogenetics of opioid receptors and addiction

Rojas, J.César.; Aguilar, B.; Rodríguez-Maldonado, E.; Collados, Mía.Teresa., 2005:
Pharmacogenetics of oral anticoagulants

Spratlin, J.; Sawyer, M.B., 2006:
Pharmacogenetics of paclitaxel metabolism

Maitland-van der Zee, A-Hilse.; Boerwinkle, E., 2005:
Pharmacogenetics of response to statins: where do we stand?

Reynolds, G.P.; Templeman, L.A.; Godlewska, B.R., 2006:
Pharmacogenetics of schizophrenia

Serretti, A.; Zanardi, R.; Franchini, L.; Artioli, P.; Dotoli, D.; Pirovano, A.; Smeraldi, E., 2004:
Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up

Toffoli, G.; Cecchin, E., 2003:
Pharmacogenetics of stomach cancer

Goetz, M.P.; Rae, J.M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L.; Flockhart, D.A.; Desta, Z.; Perez, E.A.; Ingle, J.N., 2005:
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

Lal, S.; Jada, S.Rao.; Xiang, X.; Lim, W-Teck.; Lee, E.J.D.; Chowbay, B., 2006:
Pharmacogenetics of target genes across the warfarin pharmacological pathway

Agema, W.R.P.; Wouter Jukema, J.; de Maat, M.P.M.; Zwinderman, A.H.; Kastelein, J.J.P.; Rabelink, T.J.; van der Wall, E.E., 2004:
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis

Daly, A.K., 2004:
Pharmacogenetics of the cytochromes P450

Falkowski, A.; Kaczmarczyk, M.; Goracy, I.; Górecka-Szyld, B.; Poncyljusz, W.; Parczewski, Młosz.; Ciechanowicz, A., 2006:
Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis

Ranganathan, P., 2006:
Pharmacogenetics of therapies in rheumatoid arthritis

Wechsler, M.E.; Israel, E., 2003:
Pharmacogenetics of treatment with leukotriene modifiers

Nagar, S.; Blanchard, R.L., 2006:
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan

Bateman, C., 2005 :
Pharmacogenetics offers hope

Allorge, D.; Loriot, M-A., 2004:
Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport

Hosford, D.A.; Lai, E.H.; Riley, J.H.; Xu, C-Fang.; Danoff, T.M.; Roses, A.D., 2004:
Pharmacogenetics to predict drug-related adverse events

Kollek, R.; van Aken, J.; Feuerstein, G.; Schmedders, M., 2006:
Pharmacogenetics, adverse drug reactions and public health

Gardiner, S.J.; Begg, E.J., 2006:
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice

Corrigan, O.P., 2005:
Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report

Motulsky, A.G.; Qi, M., 2006:
Pharmacogenetics, pharmacogenomics and ecogenetics

Herranz, J.L., 2006:
Pharmacogenetics, pharmacogenomics and individualised antiepileptic therapy

Davies, S.M., 2006:
Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?

Terra, S.G.; Johnson, J.A., 2004:
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward

Mansell, M.A., 2004:
Pharmacogenetics, placebos and publication fraud

Jones, D.S.; Perlis, R.H., 2006:
Pharmacogenetics, race, and psychiatry: prospects and challenges

Clemerson, J.P.; Payne, K.; Bissell, P.; Anderson, C., 2006:
Pharmacogenetics, the next challenge for pharmacy?

West, G.B.; Harris, J.M., 1964:
Pharmacogenetics--A Fresh Approach To The Problem Of Allergy

Nahum, L.H., 1964:
Pharmacogenetics--A New Discipline

Tucker, G., 2004:
Pharmacogenetics--expectations and reality

Dzida, G., 2004:
Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases

Ainsworth, M.A.; Nielsen, O.Haagen., 2005:
Pharmacogenetics--new therapeutic possibilities

Kurland, L.; Lind, L.; Lithell, H.; Syvänen, A-Christine.; Melhus, Håkan., 2003:
Pharmacogenetics--pathway to individualized antihypertensive pharmacotherapy

Kurth, J.H., 2003:
Pharmacogenetics--the horizon

Kola, I., 2005:
Pharmacogenetics--where are we and where are we heading?

Clarke, C.A., 1962:
Pharmacogenetics-a study of inherited variability in the response to drugs

Gage, B.F., 2006:
Pharmacogenetics-based coumarin therapy

Roots, I.; Gerloff, T.; Meisel, C.; Kirchheiner, J.; Goldammer, M.; Kaiser, R.; Laschinski, G.; Brockmöller, Jürgen.; Cascorbi, I.; Kleeberg, U.; Hildebrandt, A.G., 2004:
Pharmacogenetics-based new therapeutic concepts

Scharplatz, M.; Puhan, M.; Steurer, J.; Bachmann, L.M., 2004:
Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges

Huang, Y., 2007:
Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy

Ferraccioli, G.; De Santis, M.; Tolusso, B., 2004:
Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology

Sookoian, S.; Pirola, C.J., 2005:
Pharmacogenetics/pharmacogenomics in clinical practice

Merk, H.F., 2005:
Pharmacogenetics: Important aspects for dermatology

Nolan, D.; Gaudieri, S.; Mallal, S., 2003:
Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

Adley, K.E.; Keim, M.; Williams, R.S.B., 2006:
Pharmacogenetics: defining the genetic basis of drug action and inositol trisphosphate analysis

Arnold, H.Peter.; McHale, D., 2006:
Pharmacogenetics: development issues and solutions for safe and effective medicines

Sutrop, M., 2004:
Pharmacogenetics: ethical issues

Lindpaintner, K., 2003:
Pharmacogenetics: forerunner for individualized medicine

Landau, R., 2005:
Pharmacogenetics: implications for obstetric anesthesia

Weinshilboum, R.; Wang, L., 2004:
Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity

Dowling, P., 2007:
Pharmacogenetics: it's not just about ivermectin in collies

Woodcock, J., 2006:
Pharmacogenetics: on the road to 'personalized medicine'

Corrigan, O.P.; Williams-Jones, B., 2006:
Pharmacogenetics: the bioethical problem of DNA investment banking

Holgate, S.T., 2004:
Pharmacogenetics: the new science of personalizing treatment

Ferriols Lisart, F.; Ferriols Lisart, R., 2003:
Pharmacogenetics: where are we and where are we going to?

Polonio, P., 1961:
Pharmacogenic disease in psychiatry

McLean, L.Anne.; Gathmann, I.; Capdeville, R.; Polymeropoulos, M.H.; Dressman, M., 2004:
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib

Smit, M.J.; Vischer, H.F.; Bakker, R.A.; Jongejan, A.; Timmerman, H.; Pardo, L.; Leurs, R., 2006:
Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity

Hasegawa, Y., 2003:
Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy

Impicciatore, M., 2003:
Pharmacogenomic can give children safer medicines

Yagil, Y.; Yagil, C., 2003:
Pharmacogenomic considerations for immunosuppressive therapy

Attar, M.; Lee, V.H.L., 2003:
Pharmacogenomic considerations in drug delivery

Petrovic, D.; Peterlin, B., 2004:
Pharmacogenomic considerations of the insertion/deletion gene polymorphism of the angiotensin I-converting enzyme and coronary artery disease

Yamazaki, H., 2005:
Pharmacogenomic data for personalized medicines

Joly, Y.; Knoppers, B.M., 2006:
Pharmacogenomic data sample collection and storage: ethical issues and policy approaches

Trepicchio, W.L.; Williams, G.A.; Essayan, D.; Hall, S.T.; Harty, L.C.; Shaw, P.M.; Spear, B.B.; Wang, S.Jane.; Watson, M.L., 2004:
Pharmacogenomic data submissions to the FDA: clinical case studies

Ruaño, G.; Collins, J.M.; Dorner, A.J.; Wang, S-Jane.; Guerciolini, R.; Huang, S-Mei., 2004:
Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

Leighton, J.K.; DeGeorge, J.; Jacobson-Kram, D.; MacGregor, J.; Mendrick, D.; Worobec, A., 2004:
Pharmacogenomic data submissions to the FDA: non-clinical case studies

Salerno, R.A.; Lesko, L.J., 2004:
Pharmacogenomic data: FDA voluntary and required submission guidance

Walgren, R.A.; Meucci, M.A.; McLeod, H.L., 2005:
Pharmacogenomic discovery approaches: will the real genes please stand up?

Wiwanitkit, V., 2006:
Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations

Hess, K.R.; Anderson, K.; Symmans, W.Fraser.; Valero, V.; Ibrahim, N.; Mejia, J.A.; Booser, D.; Theriault, R.L.; Buzdar, A.U.; Dempsey, P.J.; Rouzier, R.; Sneige, N.; Ross, J.S.; Vidaurre, T.; Gómez, H.L.; Hortobagyi, G.N.; Pusztai, L., 2006:
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer

Issa, A.M., 2003:
Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges

Almon, R.R.; Dubois, D.C.; Jin, J.Y.; Jusko, W.J., 2005:
Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series

Ziebuhr, W.; Xiao, K.; Coulibaly, B.; Schwarz, R.; Dandekar, T., 2004:
Pharmacogenomic strategies against resistance development in microbial infections

Pandhi, P., 2006:
Pharmacogenomic studies: hype and reality

Patowary, S., 2006:
Pharmacogenomics - therapeutic and ethical issues

Arnold, H.Peter.; Hall, S.T., 2005:
Pharmacogenomics and Clinical R&D

Haas, D.W., 2005:
Pharmacogenomics and HIV therapeutics

Sandborn, W.J., 2004:
Pharmacogenomics and IBD: TPMT and thiopurines

Aerssens, J.; Paulussen, Aée.D.C., 2005:
Pharmacogenomics and acquired long QT syndrome

Lymberis, S.C.; Parhar, P.K.; Katsoulakis, E.; Formenti, S.C., 2003:
Pharmacogenomics and breast cancer

Freund, C.L.; Clayton, E.W., 2003:
Pharmacogenomics and children: meeting the ethical challenges

Ross, J.S.; Symmans, W.Fraser.; Pusztai, L.; Hortobagyi, G.N., 2006:
Pharmacogenomics and clinical biomarkers in drug discovery and development

Iqbal, O., 2004:
Pharmacogenomics and coagulation disorders

Lenz, H-Josef., 2006:
Pharmacogenomics and colorectal cancer

Siest, G.; Jeannesson, E.; Berrahmoune, H.; Maumus, S.; Marteau, J-B.; Mohr, S.; Visvikis, S., 2004:
Pharmacogenomics and drug response in cardiovascular disorders

Camilleri, M., 2005:
Pharmacogenomics and functional gastrointestinal disorders

Yamada, M., 2003:
Pharmacogenomics and future antidepressant research

Yamada, M.; Yamada, M.; Takahashi, K.; Maruyama, Y., 2006:
Pharmacogenomics and future development of novel antidepressants

Rosell, R.; Cobo, M.; Isla, D.; Camps, C.; Massuti, B., 2006:
Pharmacogenomics and gemcitabine

Kassack, M.U., 2003:
Pharmacogenomics and gene expression analysis. Functional genome research for individual application to patients

Iyengar, S.; Abraham, W.T., 2004:
Pharmacogenomics and heart failure: tailor-made therapy?

Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W.E., 2006:
Pharmacogenomics and individualized drug therapy

White, R.M.; Wong, S.H.Y., 2005:
Pharmacogenomics and its applications

Regnstrom, K.; Burgess, D.J., 2005:
Pharmacogenomics and its potential impact on drug and formulation development

Manunta, P.; Bianchi, G., 2006:
Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives--the adducin paradigm

Iqbal, O., 2005:
Pharmacogenomics and pharmacogenetics. 1st Spanish Congress on Pharmacogenomics and Pharmacogenetics, January 23-25, 2005, Valencia, Spain

Ito, R.K.; Demers, L.M., 2004:
Pharmacogenomics and pharmacogenetics: future role of molecular diagnostics in the clinical diagnostic laboratory

Toffoli, G.; Cecchin, E., 2004:
Pharmacogenomics and stomach cancer

Penny, M.A.; McHale, D., 2005:
Pharmacogenomics and the drug discovery pipeline: when should it be implemented?

Bala, M.V.; Zarkin, G.A., 2004:
Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?

Hines, R.N.; McCarver, D.Gail., 2006:
Pharmacogenomics and the future of drug therapy

Wittkowsky, A.K., 2004:
Pharmacogenomics and the management of oral anticoagulation

Cacabelos, Rón., 2005:
Pharmacogenomics and therapeutic prospects in Alzheimer's disease

Frassetto, L.A.; Benet, L.Z., 2004:
Pharmacogenomics and transplantation: where are we?

Nebert, D.W.; Jorge-Nebert, L.; Vesell, E.S., 2003:
Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements

Petsko, G.A., 2004:
Pharmacogenomics arrives

Wong, S.H.; Wagner, M.A.; Jentzen, J.M.; Schur, C.; Bjerke, J.; Gock, S.B.; Chang, C-Che., 2003:
Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity?

Jin, M.; Gock, S.B.; Jannetto, P.J.; Jentzen, J.M.; Wong, S.H., 2006:
Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases

Komamura, K., 2006:
Pharmacogenomics for cardiovascular drugs

Kupiec, T.C.; Raj, V.; Vu, N., 2006:
Pharmacogenomics for the forensic toxicologist

Tamaoki, M.; Gushima, H.; Tsutani, K., 2004:
Pharmacogenomics in Asia

Salerno, R.A.; Lesko, L.J., 2003:
Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal

Wajapeyee, N.; Somasundaram, K., 2004:
Pharmacogenomics in breast cancer: current trends and future directions

Ansari, M.; Krajinovic, M., 2007:
Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy

Mango, R.; Vecchione, L.; Raso, B.; Borgiani, P.; Brunetti, E.; Mehta, J.L.; Lauro, R.; Romeo, F.; Novelli, G., 2005:
Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy

Shimizu, C.; Fujiwara, Y., 2006:
Pharmacogenomics in chemotherapy and drug development for breast cancer

Bondy, B., 2005:
Pharmacogenomics in depression and antidepressants

Harr, T.; Itin, P.H., 2005:
Pharmacogenomics in dermatology

Brain, N.; Dominiczak, A.F., 2005:
Pharmacogenomics in hypertension: present practicalities and future potential

Egan, L.J.; Derijks, L.J.J.; Hommes, D.W., 2006:
Pharmacogenomics in inflammatory bowel disease

McAlister, V., 2003:
Pharmacogenomics in liver transplantation

García-Campelo, R.; Alonso-Curbera, G.; Antón Aparicio, L.M.; Rosell, R., 2005:
Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy

Riese-Jorda, H.H.; Baez, J.M., 2006:
Pharmacogenomics in neuro-oncology

Anonymous, 2004:
Pharmacogenomics in psychiatry

Suarez-Kurtz, G.; Pena, S.D.J., 2006:
Pharmacogenomics in the Americas: the impact of genetic admixture

Clancy, C.E.; Kass, R.S., 2003:
Pharmacogenomics in the treatment of epilepsy

Ast, O.; Lüke, W., 2004:
Pharmacogenomics of HIV

Jamroziak, K.; Robak, T., 2004:
Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies

Flordellis, C.; Paris, H.; Karabinis, A.; Lymperopoulos, A., 2004:
Pharmacogenomics of adrenoceptors

Enoch, M-Anne., 2003:
Pharmacogenomics of alcohol response and addiction

Rudnicki, M.; Mayer, G., 2003:
Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations

Taniguchi, A.; Urano, W.; Tanaka, E.; Kamatani, N., 2007:
Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis

Pahl, A.; Benediktus, E.; Chialda, L., 2006:
Pharmacogenomics of asthma

Baker, D.E., 2003:
Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy

Bhatnagar, P.; Guleria, R.; Kukreti, R., 2006:
Pharmacogenomics of beta2-agonist: key focus on signaling pathways

Miller, C.Ryan.; McLeod, H.L., 2007:
Pharmacogenomics of cancer chemotherapy-induced toxicity

Tanaka, T.; Oka, T.; Iwao, H., 2006:
Pharmacogenomics of cardiovascular pharmacology

Pollard, H.B.; Eidelman, O.; Jacobson, K.A.; Srivastava, M., 2004:
Pharmacogenomics of cystic fibrosis

Vormfelde, S.Viktor.; Burckhardt, G.; Zirk, A.; Wojnowski, L.; Brockmöller, Jürgen., 2003:
Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research

Filigheddu, F.; Troffa, C.; Glorioso, N., 2006:
Pharmacogenomics of essential hypertension: are we going the right way?

Lentz, F.; Tran, Aès.; Rey, E.; Pons, Gérard.; Tréluyer, J-Marc., 2005:
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications

Fredericks, S.; Holt, D.W., 2003:
Pharmacogenomics of immunosuppressive drug metabolism

Schillaci, G., 2004:
Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy

Yan, Q., 2003:
Pharmacogenomics of membrane transporters an overview

Pinsonneault, J.; Sadée, W., 2004:
Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome

Bianchi, G.; Staessen, J.A.; Patrizia, F., 2003:
Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future

Furuta, T.; Shirai, N.; Sugimoto, M.; Ohashi, K.; Ishizaki, T., 2004:
Pharmacogenomics of proton pump inhibitors

Pickar, D., 2003:
Pharmacogenomics of psychiatric drug treatment

Li, L.; Xie, Y-cai.; Lu, G-ping., 2006:
Pharmacogenomics of statin therapy

Marzolini, C.; Tirona, R.G.; Kim, R.B., 2004:
Pharmacogenomics of the OATP and OAT families

Bougnères, P., 2004:
Pharmacogenomics of the growth hormone: polymorphism of the receptor in the front line

Ranganathan, P., 2005:
Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

Katoh, M.; Katoh, M., 2004:
Pharmacogenomics on gastric cancer

Traynor, K., 2006:
Pharmacogenomics technique predicts chemotherapy success

Winkelmann, B.R., 2003 :
Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions

Meurer, M.J., 2004:
Pharmacogenomics, genetic tests, and patent-based incentives

Preskorn, S.H., 2006:
Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future

Dubey, A.Kumar.; Palaian, P.Subish.; Shankar, P.Ravi., 2006:
Pharmacogenomics--a new approach towards personalized medicine

Bolonna, A.A.; Arranz, M.J.; Mancama, D.; Kerwin, R.W., 2005:
Pharmacogenomics--can genetics help in the care of psychiatric patients?

Sutphin, S.D.; Smith, K.M., 2005:
Pharmacogenomics-Potential applications to orthopedic practice

Couzin, J., 2004:
Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim

Anonymous, 2006:
Pharmacogenomics. Examining genes to personalize drugs

Kaiser, J., 2003:
Pharmacogenomics. FDA puts the brakes on Roche's gene array test

Service, R.F., 2005:
Pharmacogenomics. Going from genome to pill

Krüth, P.; Wehling, M., 2003:
Pharmacogenomics. What is relevant for the internal medicine specialist?

Hernandez-Boussard, T.; Klein, T.E.; Altman, R.B., 2006:
Pharmacogenomics: The relevance of emerging genotyping technologies

Gupta, S.; Jain, S.; Brahmachari, S.K.; Kukreti, R., 2005:
Pharmacogenomics: a path to predictive medicine for schizophrenia

Bepler, G., 2006:
Pharmacogenomics: a reality or still a promise?

Grimaldi, B.A., 2007:
Pharmacogenomics: an assessment of market conditions and competition

Borchardt, P.E., 2006:
Pharmacogenomics: an in-house advantage?

Ishikawa, T., 2006:
Pharmacogenomics: current status and future prospectives

Sadée, W., 2005:
Pharmacogenomics: harbinger for the era of personalized medicine?

Brock, T.Penick.; Valgus, J.M.; Smith, S.R.; Summers, K.M., 2003:
Pharmacogenomics: implications and considerations for pharmacists

Johnson, K.; Thompson, J.; Power, A., 2005:
Pharmacogenomics: integration into drug discovery and development

Mahlknecht, U.; Voelter-Mahlknecht, S., 2005:
Pharmacogenomics: questions and concerns

Loriot, M-Anne.; Beaune, P., 2004 :
Pharmacogenomics: the link between genes and response to drugs

López-López, M.; Guerrero-Camacho, J.L.; Familiar-López, I.M.; Jung-Cook, H.; Corona-Vázquez, T.; Alonso-Vilatela, M.E., 2004:
Pharmacogenomics: the quest for individualized therapy

Girau Bach, L., 1955:
Pharmacognosia of Calluna vulgaris (L.) Hull (common heath) of the northeast region of Spain

Mangaldzhiev, N., 1963:
Pharmacognosic Studies On Sedum Rhodiola Dc

Gheorghiu, A.; Ionescu, M.Tiu, E.; Manuchian, M., 1964:
Pharmacognosic Study Of Cytisus Austriacus L

Depasquale, A., 1963:
Pharmacognostic Research On The Roots Of Coloquintide

San Martin Casamada, R., 1951:
Pharmacognostic examination of powders from cardiotonic drugs from plants

Kucera, M., 1956:
Pharmacognostic examination of the prochamazulenogen containing plants Achillea millefolium L. and Artemisia absinthium L

Lin, X.; Huang, Q.; Li, J.; Mo, G.; Lin, J.; Huang, R., 2005:
Pharmacognostic identification of dried twigs and leaves of Taraphochlamys affinis (Giff) Bremekhu

Chen, J-chun.; Chen, X-dong., 2003:
Pharmacognostic identification of medicinal Asteropyrum plants in China

San Martin Casamada, R., 1952:
Pharmacognostic notes on Mohammedan drugs

Negro, G., 1955:
Pharmacognostic observations on Cinnamomum Zeylanicum Cortex

Lukic, P.B., 1954:
Pharmacognostic part of the new Yugoslav pharmacopeia

Gherase, Fţa.; Spac, A.; Dorneanu, V.; Stănescu, U.; Grigorescu, E., 2004:
Pharmacognostic research of some species of Achillea. Note 1. Volatile oils analysis

Ye, C-jin.; Sun, Y-zhen.; Chen, K-li., 2006:
Pharmacognostic studies on Begonia sinensis rhizome

Scwar, C., 1955:
Pharmacognostic studies on Euphorbia peplus L

Datta, S.C.; Datta, D.; Mukerji, B., 1961:
Pharmacognostic studies on leaves of Myrtus communis Linn.--the Indian Buchu of commerce

Xie, L-Sha.; Liao, Y-Kui.; Huang, Q-Fang.; Huang, M-Chun., 2005:
Pharmacognostic studies on mangrove Acanthus ilicifolius

Kosova, V.; Chladek, M., 1957:
Pharmacognostic study of Datura metel L. & Datura innoxia Mill

Shah, C.S.; Sukkawala, V.M.; Chavan, A.R., 1962:
Pharmacognostic study of Merremia emarginata Hallier & comparison with Centella asiatica Linn

Atal, C.K.; Khanna, K.L., 1960:
Pharmacognostic study of Valeriana pyrolaefolia Decaisne

Burgueno Cela, A., 1958:
Pharmacognostic study of bardane

Cabo Torres, J., 1950:
Pharmacognostic study of rue leaf (Ruta graveolens) its principle components; rutoside and essence

Portoles Alonso, A., 1952:
Pharmacognostic study of the Spanish fraxinella (Dictamnus hispanicus, Webb); principal component; essence

Kraus, L.; Nadherny, J., 1956:
Pharmacognostic-anatomic study of the leaf of the sub-family Saniculoidea of Umbelliferae

Fu.K.C.; Hsu.S.K.; Wu.R.H.; Kao.K.B., 1964:
Pharmacognostical Studies On The Chinese Drug Ci-Lao-Yia--The Bark Of Aralia Mandshurica Rupr. Et Maxim

Li, C.; Wu, B.; Yang, J., 2003:
Pharmacognostical identification of Phyllanthus niruni

Zhou, R.; Luo, Y., 2003:
Pharmacognostical identification of Polygonum perfoliatum

Cai, Y.; Zhu, Y-lin.; Liu, D.; Teng, J-bei.; Wang, J-sheng., 2006:
Pharmacognostical identification of Vernonia patula (Dry) Merr

Zhong, G-yue.; Xu, L-shan.; Xu, G-jun.; Namba, T., 2003:
Pharmacognostical identification of "guijiu ([symbol: see text])" in Shosoin of Japan

Prasad, S.; Bhattacharya, I.C., 1961:
Pharmacognostical studies on Achyranthes aspera Linn

Tong, W.; Wang, B-rong.; Ai, T-min., 2004:
Pharmacognostical studies on Dactylicapnos scandens

Qiao, C.; Xu, L.; Wang, Z., 2003:
Pharmacognostical studies on the rhizome, root and leaf of Alpinia jianganfeng T.L. Wu

Qiao, C.; Xu, L.; Wang, Z., 2003:
Pharmacognostical studies on the root and rhizome of Globba racemosa

Hata, K.; Kozawa, M., 1961:
Pharmacognostical studies on umbelliferous plants. XVIII. On the constituents of the roots of Angelica Keiskei Koidzumi

Hata, K.; Kozawa, M.; Yen, K.Y.; Kimura, Y., 1963:
Pharmacognostical studies on umbelliferous plants. XX. Studies on Chinese drug "bvaku-shi". 5. On the coumarins of the roots of Angelica formosana Boiss. and A. anomala Lall

Simonian, V.H.; Youngken, H.W., 1953:
Pharmacognostical study of American berberis

Beltrami, L., 1958:
Pharmacognosty findings on several species of American species of Rauwolfia

Chernykh, N.A.; Zoz, I.G., 1964:
Pharmacognosy Of Convallaria

Blazek, Z.; Stary, F., 1964:
Pharmacognosy Of Folium Vincae Minoris. Iii. Total Alkaloid Content And Normalization Of The Purity And Quality Of The Drugs

Blazek, Z.; Stary, F., 1964:
Pharmacognosy Of Vinca Minor Leaves. I. Identification Of The Drug

Blazek, Z.; Stary, F., 1964:
Pharmacognosy Of Vinca Minor Leaves. Ii. Comparative Study Of The Leaves Of Some Other Species Of Vinca And Catharanthus

Efferth, T., 2006:
Pharmacognosy and molecular pharmacology of small molecules of natural origin for cancer therapy and chemoprevention

Do, Q-Tuan.; Bernard, P., 2004:
Pharmacognosy and reverse pharmacognosy: a new concept for accelerating natural drug discovery

Hladik, J., 1954:
Pharmacognosy at the Charles University

Braun, H., 1954:
Pharmacognosy for the physician

Baytop, T., 1958:
Pharmacognosy of Ephedra major Host var. procera

Loos, W., 1953:
Pharmacognosy of Gelsemium sempervirens Ait

Mehra, P.N.; Mittal, T.C., 1961:
Pharmacognosy of Indian substitutes of male fern. I. Dryopteris ramosa (Hope) C. Chr. and D. chrysocoma (Christ) C. Chr

Kaiser, H.; Geyer, H., 1955:
Pharmacognosy of copalche bark

Go, L.S.; Hegnauer, R., 1955:
Pharmacognosy of seven varieties of Datura stramonium

Tanaka, T., 2005 :
Pharmacoinformatics and pharmacogenomics

Kereiakes, D.J.; Tcheng, J.; Fry, E.T.A.; Bhatt, D.L.; Bosker, G.; Diez, J.G.; Ferguson, J.J.; Levine, G.N.; Schaer, G.L.; Zidar, J., 2003:
Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS

Mula, M.; Trimble, M.R., 2003:
Pharmacokinetic Interactions between Antiepileptic and Antidepressant Drugs

Gladtke, E.; Fleischer, K., 1964:
Pharmacokinetic Studies on Intraconchal Drug Administration

Rind, H.; Gladtke, E., 1964:
Pharmacokinetic Studies on Sulfonamide Therapy in 3-Month-Old Children

Gladtke, E., 1964:
Pharmacokinetic Testing of the Totality of Absorption by the Dost Method

Lee, J.B.; Winstead, P.Shane.; Cook, A.M., 2006:
Pharmacokinetic alterations in obesity

Inoue, A.; Saijo, Y.; Kikuchi, T.; Gomi, K.; Suzuki, T.; Maemondo, M.; Miki, M.; Sato, T.; Nukiwa, T., 2003:
Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis

Oshida, K.; Nagashima, T.; Ueda, T.; Yagata, H.; Tanabe, N.; Nakano, S.; Nikaidou, T.; Funatsu, H.; Hashimoto, H.; Miyazaki, M., 2005:
Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography

Yokoyama, Y.; Futagami, M.; Higuchi, T.; Mizunuma, H., 2006:
Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report

Black, R.E.; Gertler, R.; Wright, P.M.C.; Cancemi, M.T.; Hein, H.A.Tillmann.; Ramsay, M.A.E., 2005:
Pharmacokinetic analysis of rapacuronium and its metabolite during liver transplantation: an assessment of its potential as a pharmacodynamic probe

Kandimalla, K.K.; Curran, G.L.; Holasek, S.S.; Gilles, E.J.; Wengenack, T.M.; Poduslo, J.F., 2005:
Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation

Mudhakir, D.; Akita, H.; Khalil, I.A.; Futaki, S.; Harashima, H., 2005:
Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice

Chono, S.; Tauchi, Y.; Morimoto, K., 2006:
Pharmacokinetic analysis of the uptake of liposomes by macrophages and foam cells in vitro and their distribution to atherosclerotic lesions in mice

Caliceti, P.; Veronese, F.M., 2003:
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates

Jhee, O.Hwa.; Lee, Y.Sik.; Shaw, L.M.; Jeon, Y.Cheol.; Lee, M.Ho.; Lee, S.Hoon.; Kang, J.Seop., 2006:
Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method

Lohitnavy, M.; Lohitnavy, O.; Chaijittiprasert, K.; Taytiwat, P.; Polnok, S.; Sareekan, K., 2003:
Pharmacokinetic and bloequivalence studies of generic clarithromycin tablets in healthy male volunteers

Musch, E.; Loos, U.; Alléra, A.; Hügl, E.; Pütz, I.; Malek, M., 1989:
Pharmacokinetic and cell-biological investigation of prednimustine compared to its components chlorambucil and prednisolone

Neu, H.C., 1989:
Pharmacokinetic and clinical studies of cefixime: a worldwide review

Federspil, P.; Koch, A.; Schedler, M.; Tiesler, E., 1989:
Pharmacokinetic and clinical studies on timentin in ear, nose and throat infections

Begué, P.; Béfékadu, E.; Laplane, R., 1977:
Pharmacokinetic and clinical study of cefazoline in children

Gusella, M.; Crepaldi, G.; Barile, C.; Bononi, A.; Menon, D.; Toso, S.; Scapoli, D.; Stievano, L.; Ferrazzi, E.; Grigoletto, F.; Ferrari, M.; Padrini, R., 2006:
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer

Miyamoto, Y.; Uno, T.; Yamamoto, H.; Xiao-Kang, L.; Sakamoto, K-Ichi.; Hashimoto, H.; Takenaka, H.; Kawashima, Y.; Kawarasaki, H., 2004:
Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres

Parac-Vogt, T.N.; Vander Elst, L.; Kimpe, K.; Laurent, S.; Burtéa, C.; Chen, F.; Van Deun, R.; Ni, Y.; Muller, R.N.; Binnemans, K., 2006:
Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity

Shitara, Y.; Sugiyama, Y., 2006:
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

Ohno, Y.; Iga, T.; Yamada, Y.; Nagahara, M.; Araie, M.; Takayanagi, R., 2005:
Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG)

Pea, F.; Pavan, F.; Lugatti, E.; Dolcet, F.; Talmassons, G.; Screm, M.Consuelo.; Furlanut, M., 2006:
Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis

Metra, M.; Dei Cas, L.; Cleland, J.G.F., 2006:
Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter

Gan, T.J., 2006:
Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation

Ebi, H.; Sigeoka, Y.; Saeki, T.; Kawada, K.; Igarashi, T.; Usubuchi, N.; Ueda, R.; Sasaki, Y.; Minami, H., 2005:
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR)

Mahmood, I.; Green, M.D., 2005:
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins

Jin, F.; Tayab, Z.R.; Balthasar, J.P., 2006:
Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia

Svetyĭ, L.I.; Alekhin, S.N., 2003:
Pharmacokinetic and pharmacodynamic effects of isradipine in patients with arterial hypertension

Schall, U.; Pries, E.; Katta, T.; Klöppel, A.; Gastpar, M., 1996:
Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone

McKinnon, P.S.; Davis, S.L., 2004:
Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases

Nuermberger, E.; Grosset, J., 2004:
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections

Moise, P.A.; Schentag, J.J., 2006:
Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy

Molinengo, L., 1960:
Pharmacokinetic and pharmacodynamic observations on surface local anesthetics. II. Dose-effect ratios and time-effect ratios as means for the measurement of pharmacodynamic constants

Molinengo, L., 1960:
Pharmacokinetic and pharmacodynamic observations on surface local anesthetics. Note 1. Mechanism of fixation and detoxication

Derom, E.; Pauwels, R.A., 2005:
Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices

Haas, C.E.; Forrest, A., 2006:
Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need

Lin, J.H., 2007:
Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy

Lewis, A.L.; Taylor, R.R.; Hall, B.; Gonzalez, M.Victoria.; Willis, S.L.; Stratford, P.W., 2006:
Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization

Kurowski, M.; Sternfeld, T.; Sawyer, A.; Hill, A.; Möcklinghoff, C., 2003:
Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers

Boucher, B.A.; Wood, G.Christopher.; Swanson, J.M., 2006:
Pharmacokinetic changes in critical illness

Lee, E.J.; Kim, E.J.; Kim, Y.G.; Chung, H.C.; Kim, S.H.; Kim, D.H.; Lee, I.; Kim, S.G.; Lee, M.G., 2004:
Pharmacokinetic changes of intravenous 2-(allylthio) pyrazine, a chemoprotective agent, in rats with acute renal failure induced by uranyl nitrate

Surma, M.J.; Wiewiórka, J.; Szadkowska, A.; Liniecki, J., 2003:
Pharmacokinetic characteristics of 99mTc-Ethylene-l-dicysteine (99mTc-EC)

Ren, P.; Huang, X.; Li, S-Qing.; Xu, S-Yun.; Wan, M-Hua.; Zhou, Y-Xiong.; Zhou, Y-Wu.; Tang, W-Fu., 2006:
Pharmacokinetic characteristics of ferulic acid in patients with different syndromes of deficiency of spleen qi, stagnation of liver qi and spleen deficiency, and excess of stomach heat

MacGregor, T.R.; Sabo, J.P.; Norris, S.H.; Johnson, P.; Galitz, L.; McCallister, S., 2005:
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers

Chaná, P.; Fierro, Aélica.; Reyes-Parada, M.; Sáez-Briones, P., 2003:
Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study

Tatami, S.; Yamamura, N.; Sarashina, A.; Yong, C-Loi.; Igarashi, T.; Tanigawara, Y., 2004:
Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method

Minami, H.; Ebi, H., 2005:
Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)

Telatyńska-Smieszek, Bła., 2003:
Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension

Hamidi, M.; Azadi, A.; Rafiei, P., 2006:
Pharmacokinetic consequences of pegylation

Boffito, M.; Moyle, G.J., 2004:
Pharmacokinetic considerations for combining 2 protease inhibitors

Motl, S.; Zhuang, Y.; Waters, C.M.; Stewart, C.F., 2006:
Pharmacokinetic considerations in the treatment of CNS tumours

Wolraich, M.L.; Doffing, M.A., 2004:
Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate

Gilman, J.T.; Duchowny, M.; Campo, A.E., 2003:
Pharmacokinetic considerations in the treatment of childhood epilepsy

Toma, M.B.; Smith, K.M.; Martin, C.A.; Rapp, R.P., 2006:
Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis

Launay-Vacher, V.; Izzedine, H.; Deray, G., 2005:
Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure

Staatz, C.E.; Tett, S.E., 2005:
Pharmacokinetic considerations relating to tacrolimus dosing in the elderly

Perlík, F.; Masri, M.A.; Rost, M.; Kamarád, Vĕch., 2006:
Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients

Furneri, P.M.; Roccasalva, L.; Fallica, L.; Tempera, G., 1989:
Pharmacokinetic data and therapeutic efficacy of miocamycin: serum, urinary and prostatic levels. Therapeutic aspects in acute urethral syndrome and non-gonococcal urethritis

Shi, J-Min.; Lai, S-Guo.; Xu, C-Jiang.; Duan, G-Li.; Li, D., 2004:
Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats

Hey, H.; Schmedes, A.; Lund, E.D.; Haslund-Vinding, P., 2005:
Pharmacokinetic differences in the ingestion of alcopops versus pure ethanol

Obaid, R.; Ali, O.; Saify, Z.Saied.; Kamil, N.; Khan, M.Hameed.; Ahmed, T.; Ahmed, S.Waseemuddin., 2006:
Pharmacokinetic differences of some generic tablet gliclazide 80 mg on Pakistani population

Schechter, T.; Finkelstein, Y.; Doyle, J.; Verjee, Z.; Moretti, M.; Koren, G.; Dupuis, L.Lee., 2007:
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation

Blincoe, C.; Chidambaram, M.; Salari, H.; Bond, K.B.; Evans, D.T.; Gray-Kaufman, R.A.; Griffey, H.Brent.; Tranby, S.Gilbreth.; Garner-Johnson, B.; Lee, T.; Sorenson, J.R.J., 2004:
Pharmacokinetic distribution of 67Cu(II)2[3,5-diisopropyl(carboxy-14C)salicylate]4 among murine tissues

Turnheim, K., 2006:
Pharmacokinetic dosage guidelines for elderly subjects

Karie, S.; Launay-Vacher, V.; Kozlovskaia, N.L.; Izzedine, H.; Deray, G.; Shilov, E.M., 2005:
Pharmacokinetic drug changes in patients with renal failure

Ludbrook, G.L.; Upton, R.N., 2003:
Pharmacokinetic drug interaction between propofol and remifentanil?

Blume, H.; Donath, F.; Warnke, Aé.; Schug, B.S., 2006:
Pharmacokinetic drug interaction profiles of proton pump inhibitors

Zhang, H.; Cui, D.; Wang, B.; Han, Y-Hae.; Balimane, P.; Yang, Z.; Sinz, M.; Rodrigues, A.David., 2007:
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug

Swaisland, H.C.; Ranson, M.; Smith, R.P.; Leadbetter, J.; Laight, A.; McKillop, D.; Wild, M.J., 2005:
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

Armstrong, S.C.; Cozza, K.L., 2003:
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II

Armstrong, S.C.; Cozza, K.L., 2003:
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I

Ma, Q.; Okusanya, O.O.; Smith, P.F.; Dicenzo, R.; Slish, J.C.; Catanzaro, L.M.; Forrest, A.; Morse, G.D., 2006:
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

Halcomb, S.Eliza.; Sivilotti, M.L.A.; Goklaney, A.; Mullins, M.E., 2005:
Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose

Napolov, I.K.; Korobkova, I.Z.; Cherkavskaia, O.V.; Kalinichev, S.A., 2006:
Pharmacokinetic essentials of adverse reactions of radiopaque contrast agents

Kong, L.; Cooperwood, J.S.; Huang, S-Hui.Christine.; Chu, C.K.; Boudinot, F.Douglas., 2003:
Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine

Hammond, L.A., 2003:
Pharmacokinetic evaluation of gefitinib when administered with chemotherapy

Cattel, L.; Airoldi, M.; Delprino, L.; Passera, R.; Milla, P.; Pedani, F., 2006:
Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors

Krishnaiah, Y.S.R.; Muzib, Y.Indira.; Bhaskar, P.; Satyanarayana, V.; Latha, K., 2003:
Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of tinidazole in healthy human volunteers

Krishnaiah, Y.S.R.; Veer Raju, P.; Dinesh Kumar, B.; Jayaram, B.; Rama, B.; Raju, V.; Bhaskar, P., 2004:
Pharmacokinetic evaluation of guar gum-based colon-targeted oral drug delivery systems of metronidazole in healthy volunteers

Novelli, A.; Adembri, C.; Livi, P.; Fallani, S.; Mazzei, T.; De Gaudio, A.Raffaele., 2005:
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis

Leather, H.; Boyette, R.M.; Tian, L.; Wingard, J.R., 2006:
Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients

Kolyvanov, G.B., 2004:
Pharmacokinetic evaluation of the tablet dosage forms of gidazepam prepared by various technologies

Tseng, A.H.; Harding, J.W.; Craft, R.M., 2004:
Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats

Wyllie, M., 2003:
Pharmacokinetic fixes for pharmacodynamic deficits

Beier, M.T., 2005:
Pharmacokinetic interaction and erythromycin-induced sudden cardiac death: implications for practice

Reyderman, L.; Kosoglou, T.; Boutros, T.; Seiberling, M.; Statkevich, P., 2004:
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

Federico, S.; Carrano, R.; Capone, D.; Gentile, A.; Palmiero, G.; Basile, V., 2006:
Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation

Zarychanski, R.; Wlodarczyk, K.; Ariano, R.; Bow, E., 2006:
Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate

Llinares-Tello, F.; Hernández-Prats, C.; Pastor-Climente, I.; Escrivá-Moscardó, S., 2007:
Pharmacokinetic interaction between phenitoin and dexibuprofen resulting in acute neurologic toxicity

Mallolas, J.; Sarasa, M.; Nomdedeu, M.; Soriano, A.; López-Púa, Y.; Blanco, J.L.; Martínez, E.; Gatell, J.M., 2007:
Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients

Kunicki, Pł.K.; Sobieszczańska-Małek, Młgorzata., 2005:
Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient

Llinares Tello, F.; Bosacoma Ros, N.; Hernández Prats, C.; Climent Grana, E.; Selva Otaolaurruchi, J.; Ordovás Baines, J.P., 2003:
Pharmacokinetic interaction between valproic acid and carbapenem-like antibiotics: a discussion of three cases

Cabanes Mariscal, M.A.; Sánchez López, P.; Alvarez Herranz, P.; Chamorro Merino, G., 2006:
Pharmacokinetic interaction between valproic acid and ertapenem

Perea Falomir, M.; Roura Poch, P.; Higueruelo Demasón, S.; García Gil, V.J., 2006:
Pharmacokinetic interaction between valproic acid and imipenem

Clause, D.; Decleire, P-Yves.; Vanbinst, R.; Soyer, Aélie.; Hantson, P., 2005:
Pharmacokinetic interaction between valproic acid and meropenem

Khurana, M.; Lal, J.; Kamboj, V.P.; Nityanand, S.; Gupta, R.C., 2003:
Pharmacokinetic interaction of tetracycline with centchroman in healthy female volunteers

Rasmussen, B.Buur.; Larsen, L.Seiding.; Senderovitz, T., 2005:
Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers

Leucuţa, A.; Vlase, L.; Farcău, D.; Nanulescu, M., 2004:
Pharmacokinetic interaction study between ranitidine and metoclopramide

Maas, B.; Kerr, T.; Fairbairn, N.; Montaner, J.; Wood, E., 2006:
Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence

Obua, C.; Ntale, M.; Lundblad, M.S.; Mahindi, M.; Gustafsson, L.L.; Ogwal-Okeng, J.W.; Anokbonggo, W.W.; Hellgren, U., 2006:
Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda

Frassetto, L.; Thai, T.; Aggarwal, A.M.; Bucher, P.; Jacobsen, W.; Christians, U.; Benet, L.Z.; Floren, L.C., 2004:
Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects

Calabresi, L.; Pazzucconi, F.; Ferrara, S.; D.P.olo, A.; Tacca, M.Del.; Sirtori, C., 2004:
Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers

Wanke, C., 2004:
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, by Fichtenbaum et al

Steinborn, B., 2005:
Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents

Bialer, M.; Doose, D.R.; Murthy, B.; Curtin, C.; Wang, S-Sheng.; Twyman, R.E.; Schwabe, S., 2004:
Pharmacokinetic interactions of topiramate

Scheen, Aé.J., 2007:
Pharmacokinetic interactions with thiazolidinediones

Wiegand, Hörg.; Wirz, B.; Schweitzer, A.; Gross, G.; Perez, M.I.Rodriguez.; Andres, H.; Kimmerlin, T.; Rueping, M.; Seebach, D., 2006:
Pharmacokinetic investigation of a 14C-labelled beta 3/alpha tetrapeptide in rats

Sathyan, G.; Xu, E.; Thipphawong, J.; Gupta, S.K., 2007:
Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone

Li, Q.; Lugt, C.B.; Looareesuwan, S.; Krudsood, S.; Wilairatana, P.; Vannaphan, S.; Chalearmrult, K.; Milhous, W.K., 2005:
Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria

Barbacioru, C.; Arunachalam, A.; Cowden, D.; Kahwash, E.; Saltz, J.H., 2004:
Pharmacokinetic mapping of breast tumors: a new statistical analysis technique for dynamic magnetic resonance imaging

Yang, X-Xia.; Hu, Z-Ping.; Chan, S.Yung.; Duan, W.; Ho, P.Chi-Liu.; Boelsterli, U.Alex.; Ng, K-Yun.; Chan, E.; Bian, J-Song.; Chen, Y-Zong.; Huang, M.; Zhou, S-Feng., 2006:
Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide

Wikinski, S., 2005 :
Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. The role of P-glycoprotein

Murthy, B.P.; Skee, D.M.; Danyluk, A.P.; Brett, V.; Vorsanger, G.J.; Moskovitz, B.L., 2007:
Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol

Jin, F.; Krzyzanski, W., 2004:
Pharmacokinetic model of target-mediated disposition of thrombopoietin

Gallo, J.M.; Vicini, P.; Orlansky, A.; Li, S.; Zhou, F.; Ma, J.; Pulfer, S.; Bookman, M.A.; Guo, P., 2004:
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors

Andersen, M.E.; Clewell, H.J.; Tan, Y-Mei.; Butenhoff, J.L.; Olsen, G.W., 2006:
Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives

Tsuchiya, H.; Kuwata, K.; Nagayama, S.; Yamashita, K.; Kamiya, H.; Harashima, H., 2004:
Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor

Urien, S.; Rezaí, K.; Lokiec, Fçois., 2005:
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer

Urien, S.; Laurent, N.; Barre, J.; Druguet, M.; Bouvier D'yvoire, M.; Maire, P., 2004:
Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients

Muneoka, K.; Shirai, Y.; Yokoyama, N.; Wakai, T.; Hatakeyama, K., 2005:
Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report

Muneoka, K.; Shirai, Y.; Wakai, T.; Yokoyama, N.; Okumura, S.; Hatakeyama, K., 2005:
Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs

Fernández Megía, M.J.; Alós Almiñana, M.; Esquer Borrás, J., 2005:
Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma

Fox, A.W.; Kori, S.H., 2005:
Pharmacokinetic opportunities for combination therapy in migraine

Nyholm, D., 2006:
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update

Jia, G.; Heverhagen, J.T.; Henry, H.; Polzer, H.; Baudendistel, K.T.; von Tengg-Kobligk, H.; Levine, A.L.; Rosol, T.J.; Knopp, M.V., 2006:
Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI

Leth, F.Van.; Kappelhoff, B.S.; Johnson, D.; Losso, M.H.; Boron-Kaczmarska, A.; Saag, M.S.; Livrozet, J-M.; Hall, D.B.; Leith, J.; Huitema, A.D.R.; Wit, F.W.; Beijnen, J.H.; Lange, J.M.A., 2006:
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy

Panomvana Na Ayudhya, D.; Suwanmanee, J.; Visudtibhan, A., 2006:
Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children

Beccari, E.; Segre, G., 1961:
Pharmacokinetic periodism

Morabito, S.; Guzzo, I.; Vitaliano, E.; Muzi, L.; Solazzo, A.; Pistolesi, V.; Pierucci, A., 2006:
Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT)

Ereshefsky, L.; Mannaert, E., 2005:
Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system

Siafaka, I.; Rellia, P.; Argyra, E.; Iakovidou, N.; Sykiotis, C.; Vadalouka, A., 2006:
Pharmacokinetic profile and efficacy of a fentanyl transdermal delivery system for acute postoperative pain after intra-abdominal gynecologic surgery for cancer

Sathyan, G.; Xu, E.; Thipphawong, J.; Gupta, S.K., 2007:
Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food

Walls, C.; Lewis, A.; Bullman, J.; Boswell, D.; Summers, S.J.; Dow, A.; Sidhu, J., 2004:
Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers

Reoux, J.P.; Saxon, A.J.; Shen, D., 2006:
Pharmacokinetic profile of an oral loading dose of divalproex sodium during acute alcohol withdrawal

Delbaldo, C.; Pierga, J-Yves.; Dieras, Véronique.; Faivre, S.; Laurence, Vérie.; Vedovato, J-Claude.; Bonnay, M.; Mueser, M.; Nolting, A.; Kovar, A.; Raymond, E., 2005:
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

Persiani, S.; D'Amato, M.; Jakate, A.; Roy, P.; Wangsa, J.; Kapil, R.; Rovati, L.C., 2006:
Pharmacokinetic profile of dexloxiglumide

Wiltshire, H.; Hirankarn, S.; Farrell, C.; Paya, C.; Pescovitz, M.D.; Humar, A.; Dominguez, E.; Washburn, K.; Blumberg, E.; Alexander, B.; Freeman, R.; Heaton, N., 2005:
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

Bronstein, M.; Musolino, N.; Jallad, R.; Cendros, J.M.; Ramis, J.; Obach, R.; Leselbaum, A.; Catus, F., 2005:
Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

Mannaert, E.; Vermeulen, A.; Remmerie, B.; Bouhours, P.; Levron, J.C., 2006:
Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration

Massie, J.; Cranswick, N., 2006:
Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis

Okada, Y.; Kawamoto, M.; Fujii, K.; Yuge, O., 2003:
Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults

Shimizu, T.; Miyashita, I.; Matsubara, Y.; Ikeda, M.; Yamaguchi, M., 2006:
Pharmacokinetic profile of silodosin in clinical practice

Penetar, D.M.; Teter, C.J.; Ma, Z.; Tracy, M.; Lee, D.Y-W.; Lukas, S.E., 2006:
Pharmacokinetic profile of the isoflavone puerarin after acute and repeated administration of a novel kudzu extract to human volunteers

Tomlinson, B.; Thomas, N.G.; Lan, I.W.; Barbanoj, M.; Antonijoan, R.M.; Drazna, E.; Ramis, J.; Obach, R.; Peraire, Cón., 2006:
Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency

Chen, J-W.; Lauritzen, T.; Christiansen, J.J.; Jensen, L.H.; Clausen, W.H.O.; Christiansen, J.S., 2005:
Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study

Seydel, J.K., 1972:
Pharmacokinetic properties and their relation to certain physicochemical properties

Darwish, M.; Kirby, M.; Robertson, P.; Tracewell, W.; Jiang, J.G., 2006:
Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers

Burger, H.; Nooter, K., 2004:
Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

Hing, J.P.; Piotrovsky, V.; Kimko, H.; Brashear, H.Robert.; Zhao, Q., 2005:
Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation

Iakovleva, I.I.; Timokhov, V.S., 2005:
Pharmacokinetic simulation of different modes of renal replacement therapy

Kunisawa, T.; Nagata, O.; Iwasaki, H., 2006:
Pharmacokinetic simulation of high-dose administration of dexmedetomidine for decubitus treatment

Proost, J.H., 2006:
Pharmacokinetic simulations and AUC: center specificity in the limited sampling model

Groninger, E.; Proost, J.H.; de Graaf, S.S.N., 2004:
Pharmacokinetic studies in children with cancer

Rolan, P., 2004:
Pharmacokinetic studies in migraine: what questions should physicians ask?

Pang, H.; Wang, H.L.; Fu, L.; Su, C.Y., 2003:
Pharmacokinetic studies of 20(R)-ginsenoside RG3 in human volunteers

Nnane, I.P.; Kadaba, P.K., 2003:
Pharmacokinetic studies of a novel anticonvulsant, 2-(4-chlorophenyl)amino-2-(4-pyridyl)ethane, in rats

Shao, W.; Xu, W.; Li, A.; Xi, Y.; Wang, C., 2005:
Pharmacokinetic studies of quercetin-hydroxypropyl-beta-cyclodextrin inclusion compound in rats

Goudemand, J.; Scharrer, I.; Berntorp, E.; Lee, C.A.; Borel-Derlon, A.; Stieltjes, N.; Caron, C.; Scherrmann, J.M.; Bridey, F.; Tellier, Z.; Federici, A.B.; Mannucci, P.M., 2005:
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods

Bergström, M.; Långström, B., 2005:
Pharmacokinetic studies with PET

Ansari, M.T.; Loothar, B.A.; Khan, Q.J., 2006:
Pharmacokinetic study about interaction of Naproxen and Isoniazid

Sharma, S.; Thawani, V.; Hingorani, L.; Shrivastava, M.; Bhate, V.R.; Khiyani, R., 2004:
Pharmacokinetic study of 11-Keto beta-Boswellic acid

Yokoyama, K.; Miyatake, S-Ichi.; Kajimoto, Y.; Kawabata, S.; Doi, A.; Yoshida, T.; Asano, T.; Kirihata, M.; Ono, K.; Kuroiwa, T., 2006:
Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT

Moreno, J.; Belmont, A.; Jaimes, O.; Santos, Jé.A.; López, G.; Campos, Mía.G.; Amancio, O.; Pérez, P.; Heinze, G., 2004:
Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment

Braybrooke, J.P.; Levitt, N.C.; Joel, S.; Davis, T.; Madhusudan, S.; Turley, H.; Wilner, S.; Harris, A.L.; Talbot, D.C., 2003:
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression

Fujimiya, T.; Ohbora, Y.; Shinagawa, H.; Aki, T., 2003:
Pharmacokinetic study of ethanol and its metabolites during ethanol infusion

Fujimiya, T.; Shinagawa, H.; Ohbora, Y.; Aki, T., 2003:
Pharmacokinetic study of ethanol and its metabolites in culture cells

Ye, M.; Lin, X-xia.; Pan, H-ming.; Li, N.; Lou, F.; Jin, W.; Zheng, Y.; Wu, J-min., 2006:
Pharmacokinetic study of intraperitoneal chemotherapy with HCPT

Bassi, P.; De Marco, V.; Tavolini, I.M.; Longo, F.; Pinto, F.; Zucchetti, M.; Crucitta, E.; Marini, L.; Dal Moro, F., 2005:
Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy

Abe, Y.; Tsuji, Y.; Hisano, M.; Nakada, M.; Miura, K.; Watanabe, S.; Odajima, Y.; Iikura, Y., 2004:
Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis

Kobayashi, M.; Sakamoto, J.; Namikawa, T.; Okamoto, K.; Okabayashi, T.; Ichikawa, K.; Araki, K., 2006:
Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients

Mangel, J.; Buckstein, R.; Imrie, K.; Spaner, D.; Franssen, E.; Pavlin, P.; Boudreau, A.; Pennell, N.; Combs, D.; Berinstein, N.L., 2003:
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation

Niwa, T.; Nakamura, A.; Kato, T.; Kutsuna, T.; Katou, K.; Morita, H.; Kojima, Y.; Itoh, M., 2006:
Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy

Li, X-kun.; Xu, H.; Zhao, W.; Zheng, Q.; Huang, Y-dong.; Wu, X-ping.; Liu, C-zheng., 2003:
Pharmacokinetic study of recombinant human acidic fibroblast growth factor in rabbits by skin external use

Saint-Marcoux, F.; Knoop, C.; Debord, J.; Thiry, P.; Rousseau, A.; Estenne, M.; Marquet, P., 2005:
Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies

Lumlertgul, D.; Noppakun, K.; Rojanasthien, N.; Kanchanarattanakorn, K.; Jittikanont, S.; Manoyot, A.; Bunnachak, D.; Ophascharoensuk, V., 2006:
Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients

Kobayashi, M.; Oba, K.; Sakamoto, J.; Kondo, K.; Nagata, N.; Okabayashi, T.; Namikawa, T.; Hanazaki, K., 2007:
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

Fu, L.; Dai, Z.; Hou, S.; Wan, Y., 2004:
Pharmacokinetic study on lovastatin sustained-release tablet and sustained-release capsule in Beagal dogs

Han, G-zhu.; Ren, H-can.; Lu, Y.; Li, Y.; Xiao, S.; Ye, H-wei.; Wang, H-mu., 2006:
Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay

Aleksandrova, S.g., 2005:
Pharmacokinetic substantiation of ceftriaxone prophylaxis of hereditary syphilis

Longnecker, M.P., 2006:
Pharmacokinetic variability and the miracle of modern analytical chemistry

Perucca, E., 2006:
Pharmacokinetic variability of new antiepileptic drugs at different ages

Johannessen, S.I.; Tomson, Törn., 2006:
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Bandara, U.G.C.; Diyabalanage, S.; Hanke, C.; van Geldern, R.; Barth, J.A.C.; Chandrajith, R., 2018:
Arsenic-rich shallow groundwater in sandy aquifer systems buffered by rising carbonate waters: A geochemical case study from Mannar Island, Sri Lanka

Kuboyama, N.; Hayashi, I.; Yamaguchi, T., 2006:
Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor

Li, Y.; Pan, W.S.; Chen, S.L.; Xu, H.X.; Yang, D.J.; Chan, A.S.C., 2006:
Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats

Matsui-Sakata, A.; Ohtani, H.; Sawada, Y., 2005:
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release

Piotrovsky, V., 2005:
Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation

Romberg, R.; Olofsen, E.; Sarton, E.; den Hartigh, J.; Taschner, P.E.M.; Dahan, A., 2003:
Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences

Lötsch, Jörn., 2005:
Pharmacokinetic-pharmacodynamic modeling of opioids

Diack, C.; Bois, Fédéric.Y., 2005:
Pharmacokinetic-pharmacodynamic models for categorical toxicity data

Woloszczuk-Gebicka, B.; Wyska, E.; Grabowski, T.; Swierczewska, A.; Sawicka, R., 2006:
Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children

Banerji, U.; Walton, M.; Raynaud, F.; Grimshaw, R.; Kelland, L.; Valenti, M.; Judson, I.; Workman, P., 2005:
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Delbaldo, C.; Chatelut, E.; Ré, M.; Deroussent, A.; Séronie-Vivien, S.; Jambu, A.; Berthaud, P.; Le Cesne, A.; Blay, J-Yves.; Vassal, G., 2006:
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors

Isla, A.; Canut, Aés.; Rodríguez-Gascón, A.; Labora, A.; Ardanza-Trevijano, B.; Solinís, Mía.Angeles.; Pedraz, Jé.Luis., 2005:
Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology

del Mar Fernández de Gatta Garcia, M.; Revilla, N.; Calvo, M.Victoria.; Domínguez-Gil, A.; Sánchez Navarro, A., 2006:
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

Sánchez Navarro, A., 2005:
Pharmacokinetic/pharmacodynamic analysis to optimize antibacterial treatments: prediction of efficacy by using Montecarlo simulation techniques

Tod, M.; Farcy-Afif, M.; Stocco, J.; Boyer, N.; Bouton, Vérie.; Sinègre, M.; Marcellin, P., 2005:
Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C

Schuck, E.L.; Derendorf, H., 2005:
Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents

Isla, A.; Canut, Aés.; Gascón, A.R.; Labora, A.; Ardanza-Trevijano, B.; Solinís, M.Angelés.; Pedraz, J.Luis., 2005:
Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections

Tayab, Z.R.; Hochhaus, Günther., 2005 :
Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems

Boak, L.M.; Li, J.; Rayner, C.R.; Nation, R.L., 2007:
Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model

Toutain, P-Louis., 2003:
Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine

Mazoit, J-Xavier., 2006:
Pharmacokinetic/pharmacodynamic modeling of anesthetics in children: therapeutic implications

Tornøe, C.W.; Agersø, H.; Nielsen, H.A.; Madsen, H.; Jonsson, E.Niclas., 2005:
Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME

Mouton, J.W.; Vinks, A.A., 2005:
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration

Mégarbane, B.; Bloch, V.; Deye, N.; Baud, Fédéric.J., 2006:
Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose

Meagher, A.K.; Ambrose, P.G.; Grasela, T.H.; Ellis-Grosse, E.J., 2005:
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent

Theuretzbacher, U.; Ihle, F.; Derendorf, H., 2006:
Pharmacokinetic/pharmacodynamic profile of voriconazole

Avramis, V.I.; Panosyan, E.H., 2005:
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future

Trocóniz, I.F., 2003:
Pharmacokinetic/pharmacodynamic relationships: basic concepts

Anon, J.B.; Ferguson, B.; Twynholm, M.; Wynne, B.; Berkowitz, E.; Poole, M.D., 2006:
Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains

Hilger, R.A.; Richly, H.; Grubert, M.; Oberhoff, C.; Strumberg, D.; Scheulen, M.E.; Seeber, S., 2005:
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil

Hitzenberger, G., 1964:
Pharmacokinetics and Clinico-Therapeutic Effectiveness of 4-Sulfanilamido-5,6-Dimethoxypyrimidine

Jenne, J.W., 1964:
Pharmacokinetics And The Dose Of Isoniazid And P-Aminosalicylic Acid In The Treatment Of Tuberculosis

Plancher, A.C.; Salvi, G.; Bacuzzi, E., 1964:
Pharmacokinetics of 2-Sulfanilamido-5-Ethylpyrimidine in man

Droller, H., 1964:
Pharmacokinetics of Inhalational Anaesthetics

Hitzenberger, G.; Spitzy, K.H., 1964:
Pharmacokinetics of Penicillin G in Conventional and Extremely High Dosage

Brown, D.B.; Cai, S-Rong.; Fundakowski, C.E.; Zamboni, W.C.; Strychor, S.; McLeod, H.L., 2006:
Pharmacokinetics after endovascular lung perfusion with Cisplatin

Van Putte, B.P.; Hendriks, J.M.H.; Romijn, S.; Pauwels, B.; De Boeck, G.; Guetens, G.; De Bruijn, E.; Van Schil, P.E.Y., 2003:
Pharmacokinetics after pulmonary artery perfusion with gemcitabine

Gefvert, O.; Eriksson, B.; Persson, P.; Helldin, L.; Björner, A.; Mannaert, E.; Remmerie, B.; Eerdekens, Mëlle.; Nyberg, S., 2005:
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia

Hirano, K.; Nakamura, K.; Hasegawa, M., 2005:
Pharmacokinetics and adverse event of TS-1 administered through gastrostomy

Mackay, P.; Ynddal, L.; Andersen, J.V.; McCormack, J.G., 2003:
Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice

Zhou, M.H.; Yu, Y.Q.; Duan, G.L.; Cheng, W.B.; Xu, C.J.; Liu, X., 2003:
Pharmacokinetics and bioavailability of clinafloxacin in rats

Moon, Y.Jin.; Sagawa, K.; Frederick, K.; Zhang, S.; Morris, M.E., 2006:
Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats

Kowalski, P.; Bieniecki, M., 2006:
Pharmacokinetics and bioavailability study of L-ornithine-L-aspartate in healthy volunteers--a comparative study of two oral formulations

Kaneo, Y.; Hashihama, S.; Kakinoki, A.; Tanaka, T.; Nakano, T.; Ikeda, Y., 2006:
Pharmacokinetics and biodisposition of poly(vinyl alcohol) in rats and mice

Vallabhajosula, S.; Kuji, I.; Hamacher, K.A.; Konishi, S.; Kostakoglu, L.; Kothari, P.A.; Milowski, M.I.; Nanus, D.M.; Bander, N.H.; Goldsmith, S.J., 2005:
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Chauhan, S.C.; Jain, M.; Moore, E.D.; Wittel, U.A.; Li, J.; Gwilt, P.R.; Colcher, D.; Batra, S.K., 2005:
Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49

Jung, K-Ho.; Kim, D-Hyun.; Paik, J-Yung.; Ko, B-Ho.; Bae, J-Sang.; Choe, Y.Seong.; Lee, K-Han.; Kim, B-Tae., 2006:
Pharmacokinetics and biodistribution of a small radioiodine labeled nerve growth factor fragment

Healy, J.M.; Lewis, S.D.; Kurz, M.; Boomer, R.M.; Thompson, K.M.; Wilson, C.; McCauley, T.G., 2005:
Pharmacokinetics and biodistribution of novel aptamer compositions

Amantana, A.; Iversen, P.L., 2005:
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers

Reddy, L.Harivardhan.; Murthy, R.S.R., 2005:
Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques

Cho, H.Y.; Kang, H.A.; Lee, Y.B., 2006:
Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers

Najib, N.M.; Idkaidek, N.; Adel, A.; Admour, I'.; Astigarraga, R.E.B.; Nucci, G.De.; Alam, S.Mahmood.; Dham, R.; Qumaruzaman, 2003:
Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers

Zhou, Q.; Ruan, Z-Rong.; Yuan, H.; Jiang, B.; Xu, D-Hang., 2006:
Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations

Lotti, M., 2004:
Pharmacokinetics and blood levels of polychlorinated biphenyls

le Coutre, P.; Kreuzer, K-Anton.; Pursche, S.; Bonin, M.v.; Leopold, T.; Baskaynak, Gökben.; Dörken, B.; Ehninger, G.; Ottmann, O.; Jenke, A.; Bornhäuser, M.; Schleyer, E., 2003:
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

Jackson, D.L.; Milgrom, P.; Heacox, G.A.; Kharasch, E.D., 2006:
Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers

Xiao, J.; Horst, S.; Hinkle, G.; Cao, X.; Kocak, E.; Fang, J.; Young, D.; Khazaeli, M.; Agnese, D.; Sun, D.; Martin, E., 2005:
Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients

Hitzenberger, G.; Strolin Benedetti, M.; Jannuzzo, M.G.; Silvestri, S.; Moro, E.; Frigerio, E.; Sassella, D., 1989:
Pharmacokinetics and clinical tolerability of FCE 22101, a new penem antibiotic, in healthy volunteers after a single i.m. administration

Ternant, D.; Paintaud, G., 2005:
Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

Kambia, N.K.; Dine, T.; Odou, P.; Bah, S.; Azar, R.; Gressier, B.; Dupin-Spriet, Térèse.; Luyckx, M.; Brunet, C., 2005:
Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis

Novakova, K.; Laznicek, M.; Rypacek, F.; Machova, L., 2003:
Pharmacokinetics and distribution of 125I-PLA-b-PEO block copolymers in rats

Darwish, M.; Tempero, K.; Kirby, M.; Thompson, J., 2005:
Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers

Kraeber-Bodéré, Fçoise.; Faivre-Chauvet, A.; Ferrer, L.; Vuillez, J-Philippe.; Brard, P-Yves.; Rousseau, C.; Resche, I.; Devillers, A.; Laffont, S.; Bardiès, M.; Chang, K.; Sharkey, R.M.; Goldenberg, D.M.; Chatal, J-François.; Barbet, J., 2003:
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial

Kearney, B.P.; Yale, K.; Shah, J.; Zhong, L.; Flaherty, J.F., 2006:
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment

Hirata, S., 2004:
Pharmacokinetics and drug dosage adjustment theory in patients undergoing renal replacement therapy

Wang, J-Sheng.; DeVane, C.Lindsay., 2003:
Pharmacokinetics and drug interactions of the sedative hypnotics

Mannino, C.A.; South, S.M.; Inturrisi, C.E.; Quinones-Jenab, V., 2005:
Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats

Jahnke, K.; Wagner, T.; Bechrakis, N.E.; Willerding, G.; Coupland, S.E.; Fischer, L.; Thiel, E.; Korfel, A., 2005:
Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma

Hiraga, Y.; Yuhki, Y.; Itoh, K.; Tadano, K.; Takahashi, Y.; Mukai, M., 2006:
Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis

Zherdev, V.P.; Voronina, T.A.; Garibova, T.L.; Kolyvanov, G.B.; Litvin, A.A.; Sariev, A.K.; Tokhmakhchi, V.N.; Vasil'ev, A.E., 2003:
Pharmacokinetics and efficacy of phenazepam after transdermal and enteral administration in rats

Bösenberg, A.T.; Thomas, J.; Cronje, L.; Lopez, T.; Crean, P.M.; Gustafsson, U.; Huledal, G.; Larsson, L.E., 2005:
Pharmacokinetics and efficacy of ropivacaine for continuous epidural infusion in neonates and infants

Brenneisen, R.; Elsohly, M.A.; Murphy, T.P.; Passarelli, J.; Russmann, S.; Salamone, S.J.; Watson, D.E., 2004:
Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects

Sarno, M.J.; Bell, J.; Edelman, S.V., 2003:
Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe

Van Herpen, C.M.; Huijbens, R.; Looman, M.; De Vries, J.; Marres, H.; Van De Ven, J.; Hermsen, R.; Adema, G.J.; De Mulder, P.H., 2003:
Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells

Tran, H.; Petropoulos, D.; Worth, L.; Mullen, C.A.; Madden, T.; Andersson, B.; Choroszy, M.; Nguyen, J.; Webb, S.K.; Chan, K.Wah., 2004:
Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation

Sternieri, E.; Coccia, C.Pio.Rosario.; Pinetti, D.; Ferrari, A., 2006:
Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments

Sternieri, E.; Coccia, C.Pio.Rosario.; Pinetti, D.; Guerzoni, S.; Ferrari, A., 2006:
Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments

Boselli, E.; Breilh, D.; Rimmelé, T.; Djabarouti, S.; Toutain, Jérôme.; Chassard, D.; Saux, M-Claude.; Allaouchiche, B., 2005:
Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia

Boselli, E.; Breilh, D.; Rimmelé, T.; Djabarouti, S.; Saux, M-Claude.; Chassard, D.; Allaouchiche, B., 2005:
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia

Boselli, E.; Breilh, D.; Saux, M-Claude.; Gordien, J-Baptiste.; Allaouchiche, B., 2006:
Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia

Toyohara, J.; Gogami, A.; Hayashi, A.; Yonekura, Y.; Fujibayashi, Y., 2003:
Pharmacokinetics and metabolism of 5-125I-iodo-4'-thio-2'-deoxyuridine in rodents

Jannuzzo, M.G.; Vaiani, R.; Strolin Benedetti, M.; Carnovali, M.; Cassinelli, G.; Corigli, R., 1989:
Pharmacokinetics and metabolism of FCE 22101, a new penem antibiotic

Tsuda-Tsukimoto, M.; Ogasawara, Y.; Kume, T., 2005:
Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog

Lin, C-Chung.; Yeh, L-Tain.; Luu, T.; Lourenco, D.; Lau, J.Y.N., 2003:
Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys

Cook, C.S.; Berry, L.M.; Bible, R.H.; Hribar, J.D.; Hajdu, E.; Liu, N.W., 2003:
Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans

Lin, C-Chung.; Luu, K.; Lourenco, D.; Yeh, L-Tain., 2003:
Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys

Wu, D.; Wu, Z.; Yang, J.; Nair, V.A.; Miller, D.D.; Dalton, J.T., 2005:
Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study

Dahlin, D.C.; Rahimy, M.H., 2007:
Pharmacokinetics and metabolism of anecortave acetate in animals and humans

Moise, P.A.; Birmingham, M.C.; Schentag, J.J., 2003:
Pharmacokinetics and metabolism of moxifloxacin

Huestis, M.A., 2006:
Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol

Radhofer-Welte, S., 2003:
Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man

Bourgeois, B.F., 2003:
Pharmacokinetics and metabolism of topiramate

Jones, P.; Atack, J.R.; Braun, M.P.; Cato, B.P.; Chambers, M.S.; O'Connor, D.; Cook, S.M.; Hobbs, S.C.; Maxey, R.; Szekeres, H.J.; Szeto, N.; Wafford, K.A.; MacLeod, A.M., 2005:
Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA(A) alpha5 inverse agonist for cognitive dysfunction

Gao, H-min.; Wang, Z-min.; Tian, J., 2006:
Pharmacokinetics and metabolites of scutellarin in normal and model rats

Marín, P.; Cárceles, C.M.; Escudero, E.; Fernández-Varón, E., 2006:
Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats

Sojan, S.M.; Smyth, D.R.; Tsopelas, C.; Mudge, D.; Collins, P.J.; Chatterton, B.E., 2005:
Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin

Königsson, K.; Törneke, K.; Engeland, I.V.; Odensvik, K.; Kindahl, H., 2004:
Pharmacokinetics and pharmacodynamic effects of flunixin after intravenous, intramuscular and oral administration to dairy goats

Krähenbühl, S., 2004:
Pharmacokinetics and pharmacodynamices in the elderly

Eiseman, J.L.; Lan, J.; Lagattuta, T.F.; Hamburger, D.R.; Joseph, E.; Covey, J.M.; Egorin, M.J., 2004:
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

Curtis, L.D.; Brown, A.; Comer, M.B.; Senior, J.M.; Warrington, S.; Dawson, K.M., 2005:
Pharmacokinetics and pharmacodynamics of BB-10153, a thrombin-activatable plasminogen, in healthy volunteers

Almeida, L.; Soares-da-Silva, Pício., 2003:
Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans

Graefe-Mody, E.U.; Schühly, U.; Rathgen, K.; Stähle, H.; Leitner, J.M.; Jilma, B., 2006:
Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa

Galenko-Yaroshevskii, A.P.; Derlugov, L.P.; Ponomarev, V.V.; Dukhanin, A.S., 2003:
Pharmacokinetics and pharmacodynamics of a new local anesthetic agent

Waller, E.K.; Langston, A.A.; Lonial, S.; Cherry, J.; Somani, J.; Allen, A.J.; Rosenthal, H.; Redei, I., 2003:
Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation

Andes, D., 2006:
Pharmacokinetics and pharmacodynamics of antifungals

Talbert, R.L., 2004:
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure

Tahara, K.; Saigusa, K.; Kagawa, Y.; Taguchi, M.; Hashimoto, Y., 2006:
Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure

Johnston, A.J.; Steiner, L.A.; O'Connell, M.; Chatfield, D.A.; Gupta, A.K.; Menon, D.K., 2003:
Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients

Jackson, A.; Taylor, S.; Boffito, M., 2005:
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors

Haas, C.E.; Nelsen, J.L.; Raghavendran, K.; Mihalko, W.; Beres, J.; Ma, Q.; Forrest, A., 2006:
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients

Mayer, M.D.; Khosravan, R.; Vernillet, L.; Wu, J-Tao.; Joseph-Ridge, N.; Mulford, D.J., 2005:
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

Raybon, J.J.; Boje, K.M.K., 2006:
Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine

Peng, B.; Hayes, M.; Resta, D.; Racine-Poon, A.; Druker, B.J.; Talpaz, M.; Sawyers, C.L.; Rosamilia, M.; Ford, J.; Lloyd, P.; Capdeville, R., 2004:
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

Leary, A.C.; Stote, R.M.; Breedt, H.J.; O'Brien, J.; Buckley, B., 2005:
Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses

Leary, A.C.; Stote, R.M.; Cussen, K.; O'Brien, J.; Leary, W.P.; Buckley, B., 2006:
Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study

Murakami, M.; Furuie, H.; Matsuguma, K.; Wanibuchi, A.; Kikawa, S.; Irie, S., 2005:
Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers

Gremse, D.; Winter, H.; Tolia, V.; Gunasekaran, T.; Pan, W-Jian.; Karol, M.; Chiu, Y-Lin.; Pilmer, B.; Book, L., 2003:
Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease

Sánchez Navarro, A.; Colino Gandarillas, C-Isabel.; Alvarez Lerma, F.; Menacho, Y.Alcalde.; Domínguez-Gil, A., 2005:
Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients

Allen, T.M.; Cheng, W.W.K.; Hare, J.I.; Laginha, K.M., 2006:
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer

Czock, D.; Aisenpreis, U.; Rasche, F.M.; Jehle, P.M., 2004:
Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus

Millán, O.; Brunet, Mè.; Martorell, J.; García, F.; Vidal, E.; Rojo, I.; Plana, M.; Gallart, T.; Pumarola, T.; Miró, J.M.; Gatell, J.M., 2005:
Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir

Auret, K.; Roger Goucke, C.; Ilett, K.F.; Page-Sharp, M.; Boyd, F.; Oh, T.E., 2006:
Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain

Sica, D.A., 2005 :
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis

Mori, M.; Nishi, S.; Asada, A., 2005:
Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery

Vincent, J-Louis.; Spapen, H.D.M.H.; Creteur, J.; Piagnerelli, M.; Hubloue, I.; Diltoer, M.; Roman, A.; Stevens, E.; Vercammen, E.; Beaver, J.S., 2006:
Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial

Edick, M.J.; Gajjar, A.; Mahmoud, H.H.; van de Poll, M.E.C.; Harrison, P.L.; Panetta, J.C.; Rivera, G.K.; Ribeiro, R.C.; Sandlund, J.T.; Boyett, J.M.; Pui, C-Hon.; Relling, M.V., 2003:
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia

Gandhi, V.; Kantarjian, H.; Faderl, S.; Bonate, P.; Du, M.; Ayres, M.; Rios, M.Beth.; Keating, M.J.; Plunkett, W., 2003:
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias

Egan, T.D., 2006:
Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000

Kirchheiner, J.; Thomas, S.; Bauer, S.; Tomalik-Scharte, D.; Hering, U.; Doroshyenko, O.; Jetter, A.; Stehle, S.; Tsahuridu, M.; Meineke, I.; Brockmöller, Jürgen.; Fuhr, U., 2006:
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

Barbot, A.; Venisse, N.; Rayeh, F.; Bouquet, S.; Debaene, B.; Mimoz, O., 2003:
Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors

Czock, D.; Keller, F.; Rasche, F.Maximilian.; Häussler, U., 2005:
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

Dieterle, W.; Mann, J.; Kutz, K., 2003:
Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects

Wernevik, L.C.; Nyström, P.; Johnsson, G.; Nakanishi, T.; Eriksson, U.G., 2006:
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men

Lahlou, N., 2005:
Pharmacokinetics and pharmacodynamics of triptorelin

Nomura, T., 1992:
Pharmacokinetics and pharmacodynamics of vecuronium bromide

Hidalgo, M.; Bloedow, D., 2003:
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)

Clark, S.M.; Saade, G.R.; Snodgrass, W.R.; Hankins, G.D.V., 2006:
Pharmacokinetics and pharmacotherapy of thionamides in pregnancy

Aumais, G.; Lefebvre, M.; Massicotte, J.; Tremblay, C.; Kasbo, J.; Brunet, J-Sébastien.; Cardinal, C.; Grace, M.; Spénard, J., 2005:
Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis

Li, T.; Pang, Y.; Wang, Z.; Jia, Y.; Cheng, Q.; Sun, J., 2003:
Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers

Zhang, Z.; Chen, B-ling.; Wang, K.; Huang, Y-ling.; Fang, S-qing.; Gu, D-liang.; Fang, L.; Han, S-jun., 2003:
Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs

Li, J.S.; Sanders, S.P.; Perry, A.E.; Stinnett, S.S.; Jaggers, J.; Bokesch, P.; Reynolds, L.; Nassar, R.; Anderson, P.A.W., 2003:
Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass

Barrett, R.J.; Lamson, M.J.; Johnson, J.; Smith, W.B., 2005:
Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers

Brown, S.A.; Lipschitz, A.H.; Kenkel, J.M.; Sorokin, E.; Shepherd, G.; Grebe, S.; Oliver, L.K.; Luby, M.; Rohrich, R.J., 2004:
Pharmacokinetics and safety of epinephrine use in liposuction

Dutta, S.; Reed, R.C.; Cavanaugh, J.H., 2004:
Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration

Chow, H-H.Sherry.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S., 2003:
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals

Kenkel, J.M.; Lipschitz, A.H.; Shepherd, G.; Armstrong, V.W.; Streit, F.; Oellerich, M.; Luby, M.; Rohrich, R.J.; Brown, S.A., 2004:
Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study

Hayes, K.C.; Potter, P.J.; Hsieh, J.T.; Katz, M.A.; Blight, A.R.; Cohen, R., 2004:
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury

Bichler, J.; Spycher, M.O.; Amstutz, H-P.; Andresen, I.; Gaede, K.; Miescher, S., 2004:
Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers

Wang, L.H.; Wiznia, A.A.; Rathore, M.H.; Chittick, G.E.; Bakshi, S.S.; Emmanuel, P.J.; Flynn, P.M., 2003:
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children

Babalola, C.P.; Oladimeji, F.A.; Femi-Oyewo, M.N., 2004:
Pharmacokinetics and saliva secretion of paracetamol in healthy male Nigerians

Laliberte, K.; Arneson, C.; Jeffs, R.; Hunt, T.; Wade, M., 2004:
Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

Wang, X-ya.; Yang, L.; Cheng, Y-hao., 2004:
Pharmacokinetics and targeting characteristics of adriamycin after canine hepatic arterial embolization with adriamycin-lipiodol emulsion

Hayakawa, M.; Ito, Y.; Fujita, I.; Iseki, K.; Gando, S., 2006:
Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study

Tomson, Törn.; Battino, D., 2007:
Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium

Preskorn, S.H., 2005:
Pharmacokinetics and therapeutics of acute intramuscular ziprasidone

Anderton, M.J.; Manson, M.M.; Verschoyle, R.D.; Gescher, A.; Lamb, J.H.; Farmer, P.B.; Steward, W.P.; Williams, M.L., 2004:
Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice

Li, C-Qin.; He, L-Chong.; Deng, T., 2006:
Pharmacokinetics and tissue distribution of atractylenolide III in rats

Wu, G.; Meng, Y.; Zhu, X.; Huang, C., 2006:
Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis

Sova, P.; Chladek, J.; Zak, F.; Mistr, A.; Kroutil, A.; Semerad, M.; Slovak, Z., 2004:
Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)

von Hentig, N.; Müller, A.; Rottmann, C.; Lutz, T.; Klauke, S.; Kurowski, M.; Staszewski, S.; Harder, S., 2006:
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults

Ballow, M.; Berger, M.; Bonilla, F.A.; Buckley, R.H.; Cunningham-Rundles, C.H.; Fireman, P.; Kaliner, M.; Ochs, H.D.; Skoda-Smith, S.; Sweetser, M.T.; Taki, H.; Lathia, C., 2003:
Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%)

Beer, T.M.; Javle, M.; Lam, G.N.; Henner, W.David.; Wong, A.; Trump, D.L., 2005:
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer

Kielstein, J.T.; Czock, D.; Schöpke, T.; Hafer, C.; Bode-Böger, S.M.; Kuse, E.; Keller, F.; Fliser, D., 2005:
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis

Hurria, A.; Fleming, M.T.; Baker, S.D.; Kelly, W.Kevin.; Cutchall, K.; Panageas, K.; Caravelli, J.; Yeung, H.; Kris, M.G.; Gomez, J.; Miller, V.A.; D'Andrea, G.; Scher, H.I.; Norton, L.; Hudis, C., 2006:
Pharmacokinetics and toxicity of weekly docetaxel in older patients

Chinn, P.C.; Morena, R.A.; Santoro, D.A.; Kazules, T.; Kashmiri, S.V.S.; Schlom, J.; Hanna, N.; Braslawsky, G., 2006:
Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft

Brouwers, A.; Mulders, P.; Oosterwijk, E.; Buijs, W.; Corstens, F.; Boerman, O.; Oyen, W., 2004:
Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies

Danielson, B.G.; Beshara, S., 2003:
Pharmacokinetics and utilization of iron sucrose

Hummel, M.; Yonan, N.; Ross, H.; Miller, L.W.; Sechaud, R.; Balez, S.; Koelle, E.Ulrich.; Gerosa, G., 2007:
Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients

Dettli, L., 1963:
Pharmacokinetics as a methodological problem in basic medical education. I. Basis and capacity constants

Dettli, L., 1963:
Pharmacokinetics as a methodological problem in basic medical training. 2. Rate constants

Fleischhack, G.; Jaehde, U.; Bode, U., 2005:
Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis

Crome, P., 2006:
Pharmacokinetics in older people

Cusack, B.J., 2005:
Pharmacokinetics in older persons

De Maar, E.W., 1955:
Pharmacokinetics in parkinsonism

Kelsey, M.C., 1989:
Pharmacokinetics in the elderly with reference to the oral prodrug cefuroxime axetil

Alcorn, J.; McNamara, P.J., 2003:
Pharmacokinetics in the newborn

Song, M.; Qian, W.; Hang, T-Jun.; Zhang, Z-Xing., 2006:
Pharmacokinetics of (-)-clausenamide and its major metabolite 6-hydroxyl-clausenamide in beagle dogs by HPLC/MS

Shin, B.Soo.; Kim, C.Hwan.; Lee, M-Nyung.; Hur, M-Wook.; Lee, K.Choon.; Youn, Y.Seok.; Yoo, S.Dong., 2006:
Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration

Lee, J.; Lee, J.; Yoon, S.; Nho, K., 2006:
Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1

Rudek, M.A.; Zhao, M.; He, P.; Hartke, C.; Gilbert, J.; Gore, S.D.; Carducci, M.A.; Baker, S.D., 2005:
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies

Kim, E.J.; Chung, M.Y.; Chung, H.J.; Son, M.W.; Kwon, J.W.; Yoo, M.; Lee, M.G., 2006:
Pharmacokinetics of 7-carboxymethyloxy-3',4',5-trimethoxy flavone (DA-6034), a derivative of flavonoid, in mouse and rat models of chemically-induced inflammatory bowel disease

Du, Y.; Zhang, Q.; Chen, G.G.; Wei, P.; Tu, C.Y., 2006:
Pharmacokinetics of Astragaloside IV in rats by liquid chromatography coupled with tandem mass spectrometry

Weinz, C.; Buetehorn, U.; Daehler, H-P.; Kohlsdorfer, C.; Pleiss, U.; Sandmann, S.; Schlemmer, K-H.; Schwarz, T.; Steinke, W., 2005:
Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs

Liu, Y-Ping.; Li, Q-Sheng.; Huang, Y-Rong.; Zhou, M-Jin.; Liu, C-Xiao., 2005:
Pharmacokinetics of C-1027 in mice as determined by TCA-RA method

Salt, A.N., 2007:
Pharmacokinetics of Drug Entry into Cochlear Fluids

González-Esquivel, D.F.; Pérez, R.M.; Cook, H.Jung., 2004:
Pharmacokinetics of HEPP, a new anticonvulsant, in healthy subjects and rabbits after multiple doses

Neville, K.; Blaney, S.; Bernstein, M.; Thompson, P.; Adams, D.; Aleksic, A.; Berg, S., 2004:
Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study

Hirata, K.; Horikoshi, N.; Tominaga, K.; Sohma, K.; Yamaguchi, K.; Okazaki, M.; Furuhata, T.; Sasaki, K.; Nakano, Y.; Ishizuka, H.; Yamada, Y.; Uno, S.; Taguchi, T.; Yamamitsu, S.; Shirasaka, T., 2006:
Pharmacokinetics of S-1

Kearbey, J.D.; Wu, D.; Gao, W.; Miller, D.D.; Dalton, J.T., 2004:
Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator

Takizawa, Y.; Nishimura, H.; Morota, T.; Tomisawa, H.; Takeda, S.; Aburada, M., 2004:
Pharmacokinetics of TJ-8117 (Onpi-to), a drug for renal failure (I): Plasma concentration, distribution and excretion of [3H]-(-)epicatechin 3-O-gallate in rats and dogs

Wilkins, E., 2005:
Pharmacokinetics of Telzir (fosamprenavir)

Cheung, W.K.; Greene, D.S.; Kuye, O.; Shin, K.; Tonelli, A.P.; Houston, A.; Hibberd, M.; Faulkner, R.D.; Silber, B.M., 1989:
Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration

Cheung, W.K.; Greene, D.S.; Kuye, O.; Smith, M.P.; Holder, A.; Fernandez, P.; Houston, A.; Faulkner, R.D.; Silber, B.M., 1989:
Pharmacokinetics of YTR830H in healthy human subjects

Fernández-Varón, E.; Cárceles, C.M.; Espuny, A.; Marín, P.; Escudero, E., 2005:
Pharmacokinetics of a combination preparation of ampicillin and sulbactam in turkeys

Rayburn, W.F.; Powers, B.L.; Plasse, T.F.; Carr, D.; Di Spirito, M., 2006:
Pharmacokinetics of a controlled-release misoprostol vaginal insert at term

Chik, Z.; Johnston, A.; Tucker, A.T.; Chew, S.L.; Michaels, L.; Alam, C.A.S., 2006:
Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males

Choi, J.H.; Dresler, C.M.; Norton, M.R.; Strahs, K.R., 2003:
Pharmacokinetics of a nicotine polacrilex lozenge

van der Lee, M.; Verweel, G.; de Groot, R.; Burger, D., 2006:
Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children

Kletzel, M.; Jacobsohn, D.; Duerst, R., 2006:
Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation

Villar, A.; Aronis, S.; Morfini, M.; Santagostino, E.; Auerswald, G.; Thomsen, H.F.; Erhardtsen, E.; Giangrande, P.L.F., 2004:
Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A

Lin, J.H.; Russell, G.; Gertz, B., 2003:
Pharmacokinetics of alendronate: an overview

Takitani, K.; Nagai, K.; Kanbe, E.; Inoue, A.; Kawakami, C.; Kuno, T.; Tamai, H., 2003:
Pharmacokinetics of all-trans retinoic acid in acute promyelocytic leukemia patients on dialysis

Takitani, K.; Koh, M.; Inoue, A.; Kawakami, C.; Kuno, T.; Tamai, H., 2006:
Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia

Vidal Pla, R.; Padullés Zamora, Núria.; Sala Piñol, F.; Jardí Margaleff, R.; Rodríguez Frías, F.; Montoro Ronsano, Jé.Bruno., 2006:
Pharmacokinetics of alpha1-antitrypsin replacement therapy in severe congenital emphysema

Yang, R-Hua.; Rong, X-Zhou.; Zhang, T.; Hua, R., 2007:
Pharmacokinetics of amikacin in the subeschar tissue fluid following severe burns

Golovenko, N.Ya.; Borisyuk, I.Yu., 2006:
Pharmacokinetics of amixin after repeated peroral administration to mice

Kovarik, J.M.; Kaplan, B.; Silva, Hélio.Tedesco.; Kahan, B.D.; Dantal, J.; McMahon, L.; Berthier, S.; Hsu, C-Hung.; Rordorf, C., 2003:
Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation

Glue, P.; Fang, A.; Gandelman, K.; Klee, B., 2006:
Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers

Yang, B-Bing.; Baughman, S.; Sullivan, J.T., 2003:
Pharmacokinetics of anakinra in subjects with different levels of renal function

Tomaselli, F.; Maier, A.; Smolle-Jüttner, F-Maria., 2003:
Pharmacokinetics of antibiotics in inflamed and healthy lung tissue

Fraaij, P.L.A.; van Kampen, J.J.A.; Burger, D.M.; de Groot, R., 2005:
Pharmacokinetics of antiretroviral therapy in HIV-1-infected children

King, J.R.; Yogev, R.; Aldrovandi, G.; Chadwick, E.; Acosta, E.P., 2004:
Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube

Mirochnick, M.; Capparelli, E., 2004:
Pharmacokinetics of antiretrovirals in pregnant women

Baillie, G.Mark., 2005:
Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection

Lau, Y.Y.; Okochi, H.; Huang, Y.; Benet, L.Z., 2006:
Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism

Teramoto, T.; Fukao, T.; Tomita, Y.; Terauchi, Y.; Hosoi, K.; Matsui, E.; Aoki, M.; Kondo, N.; Mikawa, H., 2006:
Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma

Wu, H-bin.; Fang, Y-qi., 2005:
Pharmacokinetics of beta-asarone in rats

Moss, T.J.M.; Doherty, D.A.; Nitsos, I.; Harding, R.; Newnham, J.P., 2004:
Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration

Liu, Q.; Luo, G.; Wang, Y.; Ma, Y.; Zhang, R., 2006:
Pharmacokinetics of breviscapine in dogs and rabbits following single intravenous administration

Koyama, K.; Shimazu, Y.; Kikuno, T.; Kaziwara, H.; Sekiguti, H., 2003:
Pharmacokinetics of bromazepam in 57 patients with acute drug intoxication

Edsbäcker, S.; Andersson, T., 2004:
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease

Davis, G.A.; Rudy, A.C.; Archer, S.M.; Wermeling, D.P., 2004:
Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer

Camarasa, J.; Escubedo, E.; Adzet, T., 1988:
Pharmacokinetics of caffeic acid in rats by a high-performance liquid chromatography method

Hamada, C.; Hayashi, K.; Shou, I.; Inaba, M.; Ro, Y.; Io, H.; Maeda, K.; Fukui, M.; Tomino, Y., 2006:
Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients

McGilveray, I.J., 2005:
Pharmacokinetics of cannabinoids

Imbs, J-Louis.; Welsch, M.; Lates, S., 2007:
Pharmacokinetics of cardiovascular drugs in the elderly

Booranalertpaisarn, V.; Eiam-Ong, S.; Wittayalertpanya, S.; Kanjanabutr, T.; Na Ayudhya, D.Panomwana., 2004:
Pharmacokinetics of ceftazidime in CAPD-related peritonitis

Tan, A.R.; Moore, D.F.; Hidalgo, M.; Doroshow, J.H.; Poplin, E.A.; Goodin, S.; Mauro, D.; Rubin, E.H., 2006:
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

Hurria, A.; Lichtman, S.M., 2007:
Pharmacokinetics of chemotherapy in the older patient

Wagenlehner, F.M.E.; Kinzig-Schippers, M.; Tischmeyer, U.; Wagenlehner, C.; Sörgel, F.; Dalhoff, A.; Naber, K.G., 2005:
Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose

Jacobson, M.A.; Nicolau, D.P.; Sutherland, C.; Smith, A.; Aweeka, F., 2005:
Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS

Li, J.; Rayner, C.R.; Nation, R.L.; Deans, R.; Boots, R.; Widdecombe, N.; Douglas, A.; Lipman, J., 2005:
Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration

Lambiase, A.; Tirassa, P.; Micera, A.; Aloe, L.; Bonini, S., 2005:
Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats

Liu, T-zheng.; Qian, Z-yu., 2003:
Pharmacokinetics of crocetin in rats

Pescovitz, M.D.; Bumgardner, G.; Gaston, R.S.; Kirkman, R.L.; Light, S.; Patel, I.H.; Nieforth, K.; Vincenti, F., 2004:
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation

Veal, G.J.; Cole, M.; Errington, J.; Parry, A.; Hale, J.; Pearson, A.D.J.; Howe, K.; Chisholm, J.C.; Beane, C.; Brennan, B.; Waters, F.; Glaser, A.; Hemsworth, S.; McDowell, H.; Wright, Y.; Pritchard-Jones, K.; Pinkerton, R.; Jenner, G.; Nicholson, J.; Elsworth, A.M.; Boddy, A.V., 2005:
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study

Heatherington, A.C.; Dittrich, C.; Sullivan, J.T.; Rossi, G.; Schueller, J., 2006:
Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy

Huupponen, R.; Paija, O.; Salonen, M.; Björklund, H.; Rouru, J.; Anttila, M., 2003:
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration

Lu, C.C.; Tsai, C.S.; Ho, S.T.; Chueng, C.M.; Wang, J.J.; Wong, C.S.; Chang, S.Y.; Lin, C.Y., 2004:
Pharmacokinetics of desflurane uptake into the brain and body

Pope, L.E.; Khalil, M.H.; Berg, J.E.; Stiles, M.; Yakatan, G.J.; Sellers, E.M., 2004:
Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers

Hasan, S.M.Farid.; Ahmed, T.; Talib, N.; Hasan, F., 2006:
Pharmacokinetics of diclofenac sodium in normal man

Roberts, D.M.; Southcott, E.; Potter, J.M.; Roberts, M.S.; Eddleston, M.; Buckley, N.A., 2006:
Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow Oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal

Lares-Asseff, I.; Juárez-Olguín, H.; Flores-Pérez, J.; Bobadilla-Chávez, J., 2004:
Pharmacokinetics of digoxin in children with congestive heart failure aggravated by other diseases

Bicalho, B.; Guzzo, G.C.; Lilla, S.; Dos Santos, H.O.; Mendes, G.D.; Caliendo, G.; Perissutti, E.; Aiello, A.; Luciano, P.; Santagada, V.; Pereira, A.S.; De Nucci, G., 2005:
Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma

Kondoh, T.; Nakashima, M.; Sasaki, H.; Moriuchi, H., 2005:
Pharmacokinetics of donepezil in Down syndrome

Molina, J-M.; Peytavin, G.; Perusat, S.; Lascoux-Combes, C.; Sereni, D.; Rozenbaum, W.; Chene, G., 2004:
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial)

Bellibas, S.Eralp.; Siddique, Z.; Dorr, A.; Bertasso, A.; Sista, P.; Kolis, S.J.; Cotler, S.; Delora, P., 2005:
Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy

Argenti, D.; Hoppensteadt, D.; Heald, D.; Jensen, B.; Fareed, J., 2003:
Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy

Ettenger, R.; Bartosh, S.; Choi, L.; Zhu, W.; Niederberger, W.; Campestrini, J.; Bastien, M-Claude.; Schmouder, R., 2005:
Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients

Skorokhod, O.A.; Garmaeva, T'yana.Ts.; Vitvitsky, V.M.; Isaev, V.G.; Parovichnikova, E.N.; Savchenko, V.G.; Ataullakhanov, F.I., 2004:
Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia

Wang, L-qing.; Hu, Z-yi.; Yu, Q.; Guo, X.; Xiong, J.; Huang, Z-zhuang.; Cheng, Z-neng., 2005:
Pharmacokinetics of erythromycin stinoprate capsule

Wren, B.G.; Day, R.O.; McLachlan, A.J.; Williams, K.M., 2003:
Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women

Anderson, G.D.; Odegard, P.S., 2004:
Pharmacokinetics of estrogen and progesterone in chronic kidney disease

Zhu, M.; Burman, W.J.; Starke, J.R.; Stambaugh, J.J.; Steiner, P.; Bulpitt, A.E.; Ashkin, D.; Auclair, B.; Berning, S.E.; Jelliffe, R.W.; Jaresko, G.S.; Peloquin, C.A., 2004:
Pharmacokinetics of ethambutol in children and adults with tuberculosis

Zhao, Q.; Janssens, L.; Verhaeghe, T.; Brashear, H.Robert.; Truyen, L., 2005:
Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers

Morfini, M., 2003:
Pharmacokinetics of factor VIII and factor IX

Wenning, L.A.; Murphy, M.Gail.; James, L.P.; Blumer, J.L.; Marshall, J.D.; Baier, J.; Scheimann, A.O.; Panebianco, D.L.; Zhong, L.; Eisenhandler, R.; Yeh, K.C.; Kearns, G.L., 2005:
Pharmacokinetics of famotidine in infants

Orsini, J.A.; Moate, P.J.; Kuersten, K.; Soma, L.R.; Boston, R.C., 2006:
Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses--variability among horses and its clinical implications

Verbist, L.; Van Hecken, A.; De Schepper, P., 1989:
Pharmacokinetics of fleroxacin determined by biological method

Aoyama, T.; Ogata, K.; Shimizu, M.; Hatta, S.; Masuhara, K.; Shima, Y.; Kimura, K.; Matsumoto, Y., 2006:
Pharmacokinetics of fluconazole and fosfluconazole after intraperitoneal administration to peritoneal dialysis rats